

EP1029853

Publication Title:

Heteroaromatic bicyclic derivatives useful as anticancer agents

Abstract:

The invention relates to compounds of the formula 1 <CHEM> and to pharmaceutically acceptable salts and solvates thereof, wherein A, X, R<1>, R<3> and R<4> are as defined herein. The invention also relates to methods of treating abnormal cell growth in mammals by administering the compounds of formula 1 and to pharmaceutical compositions for treating such disorders which contain the compounds of formula 1. The invention also relates to methods of preparing the compounds of formula 1.

Data supplied from the esp@cenet database - <http://ep.espacenet.com>

(19)



Europäisches Patentamt
European Patent Office
Office européen des brevets



(11)

EP 1 029 853 A1

(12)

EUROPEAN PATENT APPLICATION

(43) Date of publication:
23.08.2000 Bulletin 2000/34

(51) Int Cl.7: **C07D 239/94, C07D 453/02,
C07D 451/02, A61K 31/505,
A61P 35/00**

(21) Application number: **99310574.1**

(22) Date of filing: **24.12.1999**

(84) Designated Contracting States:
**AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU
MC NL PT SE**
Designated Extension States:
AL LT LV MK RO SI

- Tom, Norma Jacqueline
Waterford, Connecticut 06385 (US)
- Cox, Eric David
Mystic, Connecticut 06355 (US)
- Bhattacharya, Samit Kumar
Groton, Connecticut 06340 (US)

(30) Priority: **27.01.1999 US 117341 P**


(71) Applicant: **Pfizer Products Inc.**
Groton, Connecticut 06340 (US)

(74) Representative: **Ruddock, Keith Stephen et al**
Pfizer Limited,
European Patent Department,
Ramsgate Road
Sandwich, Kent CT13 9NJ (GB)

(72) Inventors:
• Kath, John Charles
Waterford, Connecticut 06385 (US)

(54) **Heteroaromatic bicyclic derivatives useful as anticancer agents**

(57) The invention relates to compounds of the formula 1

**1**

and to pharmaceutically acceptable salts and solvates thereof, wherein A, X, R¹, R³ and R⁴ are as defined herein. The invention also relates to methods of treating abnormal cell growth in mammals by administering the compounds of formula 1 and to pharmaceutical compositions for treating such disorders which contain the compounds of formula 1. The invention also relates to methods of preparing the compounds of formula 1.

EP 1 029 853 A1

DescriptionBackground of the Invention

[0001] This invention relates to novel bicyclic derivatives that are useful in the treatment of abnormal cell growth, such as cancer, in mammals. This invention also relates to a method of using such compounds in the treatment of abnormal cell growth in mammals, especially humans, and to pharmaceutical compositions containing such compounds.

[0002] It is known that a cell may become cancerous by virtue of the transformation of a portion of its DNA into an oncogene (i.e., a gene which, on activation, leads to the formation of malignant tumor cells). Many oncogenes encode proteins that are aberrant tyrosine kinases capable of causing cell transformation. Alternatively, the overexpression of a normal proto-oncogenic tyrosine kinase may also result in proliferative disorders, sometimes resulting in a malignant phenotype.


[0003] Receptor tyrosine kinases are enzymes which span the cell membrane and possess an extracellular binding domain for growth factors such as epidermal growth factor, a transmembrane domain, and an intracellular portion which functions as a kinase to phosphorylate specific tyrosine residues in proteins and hence to influence cell proliferation. Other receptor tyrosine kinases include c-erbB-2, c-met, tie-2, PDGFR, FGFR, VEGF and TGF- β . It is known that such kinases are frequently aberrantly expressed in common human cancers such as breast cancer, gastrointestinal cancer such as colon, rectal or stomach cancer, leukemia, and ovarian, bronchial or pancreatic cancer. It has also been shown that epidermal growth factor receptor (EGFR), which possesses tyrosine kinase activity, is mutated and/or overexpressed in many human cancers such as brain, lung, squamous cell, bladder, gastric, breast, head and neck, oesophageal, gynecological and thyroid tumors.

[0004] Accordingly, it has been recognized that inhibitors of receptor tyrosine kinases are useful as selective inhibitors of the growth of mammalian cancer cells. For example, erbstatin, a tyrosine kinase inhibitor, selectively attenuates the growth in athymic nude mice of a transplanted human mammary carcinoma which expresses epidermal growth factor receptor tyrosine kinase (EGFR) but is without effect on the growth of another carcinoma which does not express the EGF receptor. Thus, the compounds of the present invention, which are selective inhibitors of certain receptor tyrosine kinases, are useful in the treatment of abnormal cell growth, in particular cancer, in mammals.

[0005] Various other compounds, such as styrene derivatives, have also been shown to possess tyrosine kinase inhibitory properties. More recently, five European patent publications, namely EP 0 566 226 A1 (published October 20, 1993), EP 0 602 851 A1 (published June 22, 1994), EP 0 635 507 A1 (published January 25, 1995), EP 0 635 498 A1 (published January 25, 1995), and EP 0 520 722 A1 (published December 30, 1992), refer to certain bicyclic derivatives, in particular quinazoline derivatives, as possessing anti-cancer properties that result from their tyrosine kinase inhibitory properties. Also, World Patent Application WO 92/20642 (published November 26, 1992), refers to certain bis-mono and bicyclic aryl and heteroaryl compounds as tyrosine kinase inhibitors that are useful in inhibiting abnormal cell proliferation. World Patent Applications WO96/16960 (published June 6, 1996), WO 96/09294 (published March 6, 1996), WO 97/30034 (published August 21, 1997), WO 98/02434 (published January 22, 1998), WO 98/02437 (published January 22, 1998), and WO 98/02438 (published January 22, 1998), also refer to substituted bicyclic heteroaromatic derivatives as tyrosine kinase inhibitors that are useful for the same purpose.

Summary of the Invention

[0006] The present invention relates to compounds of the formula 1



1

and to pharmaceutically acceptable salts and solvates thereof, wherein:


X is N or CH;

A represents a fused 5, 6 or 7-membered ring optionally containing 1 to 4 heteroatoms which may be the same or different and which are selected from $-N(R^1)-$, O, and $S(O)_j$, wherein j is an integer from 0 to 2, the fused ring containing a total of 1, 2 or 3 double bonds inclusive of the bond in the pyridine or pyrimidine ring to which it is fused wherein the R^1 group attached to the nitrogen is absent if a double bond includes the foregoing optional nitrogen moiety $-N(R^1)-$, with the proviso that the fused ring does not form part of a purine and that the fused ring does not contain two adjacent O or $S(O)_j$ atoms, and wherein the carbon atoms of the A moiety are optionally substituted with 1 to 3 R^5 groups;

each R^1 and R^2 is independently H or C_1-C_6 alkyl;

R^3 is $-(CR^1R^2)_m-R^8$ wherein m is 0 or 1;

or R^1 and R^3 are taken together to form a group of the formula



wherein said group is optionally substituted with 1 to 3 R^5 groups;

R^4 is $-(CR^1R^2)_t(C_6-C_{10} \text{ aryl})$ or $-(CR^1R^2)_t(4-10 \text{ membered heterocyclic})$, wherein t is an integer from 0 to 5, wherein said R^4 groups are substituted with 1 to 3 groups independently selected from $-(CR^1R^2)_qNR^1R^9$, $-(CR^1R^2)_qNR^9$ (C_1-C_6 alkanoyl), $-(CR^1R^2)_qO(CR^1R^2)_rR^9$, and $-(CR^1R^2)_qR^9$ wherein q and r are each independently an integer from 0 to 5, and wherein the heterocyclic, aryl and alkyl moieties of the foregoing groups are optionally substituted with 1 to 3 R^{10} groups;

each R^5 is independently selected from halo, hydroxy, $-NR^1R^2$, C_1-C_6 alkyl, trifluoromethyl, C_1-C_6 alkoxy, and trifluoromethoxy;

each R^6 and R^7 is independently selected from H, C_1-C_6 alkyl, $-(CR^1R^2)_t(C_6-C_{10} \text{ aryl})$, and $-(CR^1R^2)_t(4-10 \text{ membered heterocyclic})$, wherein t is an integer from 0 to 5, 1 or 2 ring carbon atoms of the heterocyclic group are optionally substituted with an oxo (=O) moiety, and the alkyl, aryl and heterocyclic moieties of the foregoing R^6 and R^7 groups are optionally substituted with 1 to 3 substituents independently selected from halo, cyano, nitro, $-NR^1R^2$, trifluoromethyl, trifluoromethoxy, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, hydroxy, and C_1-C_6 alkoxy;

each R^6 is independently selected from $-(CR^1R^2)_t(C_6-C_{10} \text{ aryl})$ and $-(CR^1R^2)_t(4-10 \text{ membered heterocyclic})$, wherein t is an integer from 0 to 5, 1 or 2 ring carbon atoms of the heterocyclic group are optionally substituted with an oxo (=O) moiety, and each of the foregoing R^8 groups is optionally substituted with 1 to 5 R^{10} groups;

R^9 is a fused or bridged bicyclic ring or a spirocyclic ring, wherein said ring contains from 5 to 12 carbon atoms in which up to 2 carbon atoms are optionally replaced with a hetero moiety selected from O, $S(O)_j$ wherein j is an integer from 0 to 2, and $-NR^{11}-$, provided that two O atoms, two $S(O)_j$ moieties, an O atom and a $S(O)_j$ moiety, an N atom and an S atom, or an N atom and an O atom are not attached directly to each other, and wherein said ring is saturated or partially unsaturated with up to two carbon-carbon double bonds, and the carbon atoms of said ring are optionally substituted with 1 to 4 R^{10} groups;


or where R^9 is as $-NR^1R^9$ then R^9 optionally can be taken together with R^1 and the nitrogen to which R^1 and R^9 are attached to form a fused or bridged bicyclic ring or a spirocyclic ring, wherein said ring is saturated and contains from 5 to 12 carbon atoms in which up to 2 carbon atoms are optionally replaced with a hetero moiety selected from O, $S(O)_j$ wherein j is an integer from 0 to 2, and $-NR^1-$, provided that two O atoms, two $S(O)_j$ moieties, or an O atom and a $S(O)_j$ moiety are not attached directly to each other, and wherein the carbon atoms of said rings are optionally substituted with 1 to 4 R^{10} groups,

each R^{10} is independently selected from halo, cyano, nitro, trifluoromethoxy, trifluoromethyl, azido, hydroxy, C_1-C_6 alkoxy, C_1-C_{10} alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, $-C(O)R^5$, $-C(O)OR^6$, $-OC(O)R^6$, $-NR^6C(O)R^7$, $-C(O)NR^6R^7$, $-NR^6R^7$, $-NR^6OR^7$, $-SO_2NR^6R^7$, $-S(O)_j(C_1-C_6 \text{ alkyl})$ wherein j is an integer from 0 to 2, $-(CR^1R^2)_t(C_6-C_{10} \text{ aryl})$, $-(CR^1R^2)_t(4-10 \text{ membered heterocyclic})$, $-(CR^1R^2)_qC(O)(CR^1R^2)_t(C_6-C_{10} \text{ aryl})$, $-(CR^1R^2)_qC(O)(CR^1R^2)_t(4-10 \text{ membered heterocyclic})$, $-(CR^1R^2)_tO(CR^1R^2)_q(C_6-C_{10} \text{ aryl})$, $-(CR^1R^2)_tO(CR^1R^2)_q(4-10 \text{ membered heterocyclic})$, $-(CR^1R^2)_qSO_2(CR^1R^2)_t(C_6-C_{10} \text{ aryl})$, and $-(CR^1R^2)_qSO_2(CR^1R^2)_t(4-10 \text{ membered heterocyclic})$, wherein q and t are each independently an integer from 0 to 5, 1 or 2 ring carbon atoms of the heterocyclic moieties of the foregoing R^{10} groups are optionally substituted with an oxo (=O) moiety, and the alkyl, alkenyl, alkynyl, aryl and heterocyclic moieties of the foregoing R^{10} groups are optionally substituted with 1 to 3 substituents independently selected

from halo, cyano, nitro, trifluoromethyl, trifluoromethoxy, azido, $-OR^6$, $-C(O)R^6$, $-C(O)OR^6$, $-OC(O)R^6$, $-NR^6C(O)R^7$, $-C(O)NR^6R^7$, $-NR^6R^7$, $-NR^6OR^7$, C_1-C_6 alkyl, C_2-C_6 alkenyl, C_2-C_6 alkynyl, $-(CR^1R^2)_t(C_6-C_{10} \text{ aryl})$, and $-(CR^1R^2)_t(4-10 \text{ membered heterocyclic})$, wherein t is an integer from 0 to 5;
 R^{11} is H, C_1-C_6 alkyl, $-C(O)R^6$ or $-SO_2R^6$;


and wherein any of the above-mentioned substituents comprising a CH_3 (methyl), CH_2 (methylene), or CH (methine) group which is not attached to a halogeno, SO or SO_2 group or to a N, O or S atom optionally bears on said group a substituent selected from hydroxy, halo, C_1-C_4 alkyl, C_1-C_4 alkoxy and $-NR^1R^2$.

[0007] In a specific embodiment of the present invention, the A moiety of the compounds of formula 1 is selected from



wherein the above A moieties bear an R^4 group as a substituent and optionally bear 1 to 3 R^5 groups as substituents.



[0008] Other specific embodiments of the compounds of formula 1 include those wherein A is selected from






wherein the above A moieties bear an R^4 group as a substituent and optionally bear 1 to 3 R^5 groups as substituents.

[0009] Other specific embodiments of the compounds of formula 1 include those wherein A is selected from




wherein the above A moieties bear an R^4 group as a substituent and optionally bear 1 to 3 R^5 groups as substituents.

[0010] Other specific embodiments of the compounds of formula 1 include those wherein A is selected from



wherein the above A moieties bear an R^4 group as a substituent and optionally bear 1 to 3 R^5 groups as substituents.

[0011] Other specific embodiments of the compounds of formula 1 include those wherein A is



wherein the above A moieties bear an R^4 group as a substituent and optionally bear 1 to 3 R^5 groups as substituents.

[0012] Other specific embodiments of the compounds of formula 1 include those wherein R^4 is $-(CR^1R^2)_t(C_6-C_{10}$ aryl) or $-(CR^1R^2)_t(4-10$ membered heterocyclic), wherein t is an integer from 0 to 5, wherein said R^4 groups are substituted with 1 to 3 groups independently selected from $-(CR^1R^2)_qNR^9$, $-(CR^1R^2)_qNR^9(C_1-C_6$ alkanoyl), $-(CR^1R^2)_qO$

(CR¹R²), R⁹ and -(CR¹R²)_qR⁹ wherein q and r are each independently an integer from 0 to 3, and wherein the heterocyclic, aryl and alkyl moieties of the foregoing groups are optionally substituted with 1 to 3 R¹⁰ groups.

[0013] Other specific embodiments of the compounds of formula 1 include those wherein R³ is -(CR¹R²)_m-R⁸ wherein m is 0 or 1 and R⁸ is selected from -(CR¹R²)_t(phenyl), -(CR¹R²)_t(pyridyl), -(CR¹R²)_t(pyrimidinyl), -(CR¹R²)_t(indolyl), -(CR¹R²)_t(indazolyl) and -(CR¹R²)_t(benzimidazolyl), wherein t is an integer from 0 to 5, and each of the foregoing R⁸ groups is optionally substituted with 1 to 5 R¹⁰ groups.

[0014] Other specific embodiments of the compounds of formula 1 include those selected from the group consisting of:

6-[4-(6-Amino-3-aza-bicyclo[3.1.0]hex-3-ylmethyl)-phenyl]-quinazolin-4-yl)-(4-phenoxy-phenyl)-amine;
 (3-[4-[4-(4-Benzyl-phenylamino)-quinazolin-6-yl]-benzyl]-3-aza-bicyclo[3.1.0]hex-6-yl)-methanol;
 (3-[4-[4-(4-Phenoxy-phenylamino)-quinazolin-6-yl]-benzyl]-3-aza-bicyclo[3.1.0]hex-6-yl)-methanol;
 (3-[4-[4-(1-Benzenesulfonyl-1H-indol-5-ylamino)-quinazolin-6-yl]-benzyl]-3-aza-bicyclo[3.1.0]hex-6-yl)-methanol;
 (6-[4-[(1-Aza-bicyclo[2.2.2]oct-3-ylamino)-methyl]-phenyl]-quinazolin-4-yl)-(4-phenoxy-phenyl)-amine;
 (6-[4-[(1-Aza-bicyclo[2.2.2]oct-3-ylamino)-methyl]-phenyl]-quinazolin-4-yl)-(4-benzyl-phenyl)-amine;
 6-[4-[(1-Aza-bicyclo[2.2.2]oct-3-ylamino)-methyl]-phenyl]-quinazolin-4-yl)-(1-benzenesulfonyl-1H-indol-5-yl)-amine;
 6-[4-[(3-Aza-bicyclo[3.1.0]hex-6-ylamino)-methyl]-phenyl]-quinazolin-4-yl)-(4-phenoxy-phenyl)-amine;
 3-[4-[4-(4-Benzyl-phenylamino)-quinazolin-6-yl]-benzyl]-8-methyl-8-aza-bicyclo[3.2.1]octan-6-ol;
 (4-Benzyl-phenyl)-6-[4-(6-methoxymethyl-3-aza-bicyclo[3.1.0]hex-3-ylmethyl)-phenyl]-quinazolin-4-yl)-amine
 {6-[4-(6-Methoxymethyl-3-aza-bicyclo[3.1.0]hex-3-ylmethyl)-phenyl]-quinazolin-4-yl)-(4-phenoxy-phenyl)-amine;
 (3-[4-[4-(4-(1,2,3)Thiadiazol-5-yl-phenylamino)-quinazolin-6-yl]-benzyl]-3-aza-bicyclo[3.1.0]hex-6-yl)-methanol;
 (3-[4-[4-(4-Cyclohexyl-phenylamino)-quinazolin-6-yl]-benzyl]-3-aza-bicyclo[3.1.0]hex-6-yl)-methanol;
 (3-[4-[4-(4-p-Tolyloxy-phenylamino)-quinazolin-6-yl]-benzyl]-3-aza-bicyclo[3.1.0]hex-6-yl)-methanol;
 (3-[4-[4-(Biphenyl-4-ylamino)-quinazolin-6-yl]-benzyl]-3-aza-bicyclo[3.1.0]hex-6-yl)-methanol;
 (3-[4-[4-(4-Ethyl-phenylamino)-quinazolin-6-yl]-benzyl]-3-aza-bicyclo[3.1.0]hex-6-yl)-methanol;
 4-[6-[4-(6-Hydroxymethyl-3-aza-bicyclo[3.1.0]hex-3-ylmethyl)-phenyl]-quinazolin-4-ylamino]-N-phenyl-benzamide;
 [3-[4-[4-[1-(Propane-2-sulfonyl)-1H-indol-5-ylamino]-quinazolin-6-yl]-benzyl]-3-aza-bicyclo[3.1.0]hex-6-yl]-methanol;
 (3-[4-[4-(1-Benzyl-1H-indazol-5-ylamino)-quinazolin-6-yl]-benzyl]-3-aza-bicyclo[3.1.0]hex-6-yl)-methanol;
 {1-Benzenesulfonyl-1H-indol-5-yl)-(6-[4-[(3-oxa-bicyclo[3.1.0]hex-6-ylamino)-methyl]-phenyl]-quinazolin-4-yl)-amine;
 8-[4-[4-(1-Benzenesulfonyl-1H-indol-5-ylamino)-quinazolin-6-yl]-benzyl]-8-aza-bicyclo[3.2.1]octan-3-ol;
 8-[4-[4-[1-(Propane-2-sulfonyl)-1H-indol-5-ylamino]-quinazolin-6-yl]-benzyl]-8-aza-bicyclo[3.2.1]octan-3-ol;
 8-[4-[4-(4-Phenoxy-phenylamino)-quinazolin-6-yl]-benzyl]-8-aza-bicyclo[3.2.1]octan-3-ol;
 8-[4-[4-(1-Benzyl-1H-indol-5-ylamino)-quinazolin-6-yl]-benzyl]-8-aza-bicyclo[3.2.1]octan-3-ol;
 (3-[4-[4-(6-Phenoxy-pyridin-3-ylamino)-quinazolin-6-yl]-benzyl]-3-aza-bicyclo[3.1.0]hex-6-yl)-methanol;
 (3-[5-[4-(4-Benzyl-phenylamino)-quinazolin-6-yl]-pyridin-2-ylmethyl]-3-aza-bicyclo[3.1.0]hex-6-yl)-methanol;
 {3-[4-(4-Phenoxy-phenylamino)-quinazolin-6-ylmethyl]-3-aza-bicyclo[3.1.0]hex-6-yl]-methanol;
 (5-[4-[4-(1-Benzenesulfonyl-1H-indol-5-ylamino)-quinazolin-6-yl]-benzyl]-5-aza-spiro[2.5]oct-1-yl)-methanol;
 (5-[4-[4-(4-Phenoxy-phenylamino)-quinazolin-6-yl]-benzyl]-5-aza-spiro[2.5]oct-1-yl)-methanol;
 (6-[4-[4-(1-Benzenesulfonyl-1H-indol-5-ylamino)-quinazolin-6-yl]-benzyl]-6-aza-spiro[2.5]oct-1-yl)-methanol;
 (6-[4-[4-(4-Phenoxy-phenylamino)-quinazolin-6-yl]-benzyl]-6-azaspiro[2.5]oct-1-yl)-methanol;
 (5-[4-[4-(1-Benzenesulfonyl-1H-indol-5-ylamino)-quinazolin-6-yl]-benzyl]-5-aza-spiro[2.4]hept-1-yl)-methanol;
 (5-[4-[4-(4-Phenoxy-phenylamino)-quinazolin-6-yl]-benzyl]-5-aza-spiro[2.4]hept-1-yl)-methanol;
 (5-[4-[4-(4-Phenoxy-phenylamino)-quinazolin-6-yl]-benzyl]-5-aza-spiro[2.5]oct-1-yl)-methanol;

and the pharmaceutically acceptable salts and solvates of the foregoing compounds.

[0015] This invention also relates to a method for the treatment of abnormal cell growth in a mammal, including a human, comprising administering to said mammal an amount of a compound of the formula 1, as defined above, or a pharmaceutically acceptable salt or solvate thereof, that is effective in treating abnormal cell growth. In one embodiment of this method, the abnormal cell growth is cancer, including, but not limited to, lung cancer, bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, colon cancer, breast cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, Hodgkin's Disease, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer


of the urethra, cancer of the penis, prostate cancer, chronic or acute leukemia, lymphocytic lymphomas, cancer of the bladder, cancer of the kidney or ureter, renal cell carcinoma, carcinoma of the renal pelvis, neoplasms of the central nervous system (CNS), primary CNS lymphoma, spinal axis tumors, brain stem glioma, pituitary adenoma, or a combination of one or more of the foregoing cancers. In another embodiment of said method, said abnormal cell growth is a benign proliferative disease, including, but not limited to, psoriasis, benign prostatic hypertrophy or restinosis.

[0016] This invention also relates to a method for the treatment of abnormal cell growth in a mammal which comprises administering to said mammal an amount of a compound of formula 1, or a pharmaceutically acceptable salt or solvate thereof, that is effective in treating abnormal cell growth in combination with an anti-tumor agent selected from the group consisting of mitotic inhibitors, alkylating agents, anti-metabolites, intercalating antibiotics, growth factor inhibitors, cell cycle inhibitors, enzymes, topoisomerase inhibitors, biological response modifiers, antibodies, cytotoxics, anti-hormones, and anti-androgens.

[0017] This invention also relates to a pharmaceutical composition for the treatment of abnormal cell growth in a mammal, including a human, comprising an amount of a compound of the formula 1, as defined above, or a pharmaceutically acceptable salt or solvate thereof, that is effective in treating abnormal cell growth, and a pharmaceutically acceptable carrier. In one embodiment of said composition, said abnormal cell growth is cancer, including, but not limited to, lung cancer, bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, colon cancer, breast cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, Hodgkin's Disease, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, prostate cancer, chronic or acute leukemia, lymphocytic lymphomas, cancer of the bladder, cancer of the kidney or ureter, renal cell carcinoma, carcinoma of the renal pelvis, neoplasms of the central nervous system (CNS), primary CNS lymphoma, spinal axis tumors, brain stem glioma, pituitary adenoma, or a combination of one or more of the foregoing cancers. In another embodiment of said pharmaceutical composition, said abnormal cell growth is a benign probe disease, including, but not limited to, psoriasis, benign prostatic hypertrophy or restinosis.


[0018] The invention also relates to a pharmaceutical composition for the treatment of abnormal cell growth in a mammal, including a human, which comprises an amount of a compound of formula 1, as defined above, or a pharmaceutically acceptable salt or solvate thereof, that is effective in treating abnormal cell growth in combination with a pharmaceutically acceptable carrier and an anti-tumor agent selected from the group consisting of mitotic inhibitors, alkylating agents, anti-metabolites, intercalating antibiotics, growth factor inhibitors, cell cycle inhibitors, enzymes, topoisomerase inhibitors, biological response modifiers, anti-hormones, and anti-androgens.

[0019] The invention also relates to a method of preparing a compound of the formula 1




1


and to pharmaceutically acceptable salts and solvates thereof, wherein A, X, R¹, R⁴ and R³ are as defined above, which comprises either (a) reacting a compound of the formula 5 with a compound of the formula 6




wherein Z is a leaving group and A, X, R¹, R³, and R⁴ are as defined above, or (b) reacting a compound of the formula 2 with a compound of the formula 6



wherein X, A, R¹, and R³ are as defined above and Z¹ is an activating group to provide an intermediate of the formula 7



wherein Z¹, X, A, R¹, and R³ are as defined above, and treating the compound of formula 7 with a coupling partner of the formula X¹-(CR¹R²)_t(C₆-C₁₀ aryl) or X¹-(CR¹R²)_t(4-10 membered heterocyclic), wherein t, R¹ and R² are as defined above as provided in the definition of R⁴, the aryl and heterocyclic groups of the foregoing groups are substituted with a group that includes an aldehyde or acid moiety, and X¹ is -B(OH)₂ or -Sn(C₁-C₅ alkyl)₃, to provide a compound of formula 8



wherein X, A, R¹, and R³ are as defined above, and Z² is -(CR¹R²)_t(C₆-C₁₀ aryl) or -(CR¹R²)_t(4-10 membered heterocyclic), wherein t, R¹ and R² are as defined above as provided in the definition of R⁴, and the aryl and heterocyclic groups of the foregoing Z² groups are substituted with a group that includes an aldehyde or acid moiety, and modifying

said acid or aldehyde moiety to introduce a group selected from $-(CR^1R^2)_qNR^9$, $-(CR^1R^2)_qNR^9(C_1-C_6 \text{ alkanoyl})$, $-(CR^1R^2)_qOR^9$, and $-(CR^1R^2)_qR^9$, wherein R^1 , R^2 , R^9 and q are as defined above.

[0020] "Abnormal cell growth", as used herein, unless otherwise indicated, refers to cell growth that is independent of normal regulatory mechanisms (e.g., loss of contact inhibition). This includes the abnormal growth of: (1) tumor cells (tumors) that proliferate by expressing a mutated tyrosine kinase or overexpression of a receptor tyrosine kinase, (2) benign and malignant cells of other proliferative diseases in which aberrant tyrosine kinase activation occurs; and (4) any tumors that proliferate by receptor tyrosine kinases.

[0021] The term "treating", as used herein, unless otherwise indicated, means reversing, alleviating, inhibiting the progress of, or preventing the disorder or condition to which such term applies, or one or more symptoms of such disorder or condition. The term "treatment", as used herein, unless otherwise indicated, refers to the act of treating as "treating" is defined immediately above.

[0022] The term "halo", as used herein, unless otherwise indicated, means fluoro, chloro, bromo or iodo. Preferred halo groups are fluoro, chloro and bromo.

[0023] The term "alkyl", as used herein, unless otherwise indicated, includes saturated monovalent hydrocarbon radicals having straight, branched, or cyclic moieties (including fused and bridged bicyclic and spirocyclic moieties), or a combination of the foregoing moieties. For an alkyl group to have cyclic moieties, the group must have at least three carbon atoms.

[0024] The term "alkenyl", as used herein, unless otherwise indicated, includes alkyl moieties having at least one carbon-carbon double bond wherein alkyl is as defined above and including E and Z isomers of said alkenyl moiety.

[0025] The term "alkynyl", as used herein, unless otherwise indicated, includes alkyl moieties having at least one carbon-carbon triple bond wherein alkyl is as defined above.

[0026] The term "alkoxy", as used herein, unless otherwise indicated, includes O-alkyl groups wherein alkyl is as defined above.

[0027] The term "aryl", as used herein, unless otherwise indicated, includes an organic radical derived from an aromatic hydrocarbon by removal of one hydrogen, such as phenyl or naphthyl.

[0028] The term "4-10 membered heterocyclic", as used herein, unless otherwise indicated, includes aromatic and non-aromatic heterocyclic groups containing one to four heteroatoms each selected from O, S and N, wherein each heterocyclic group has from 4-10 atoms in its ring system, and with the proviso that the ring of said group does not contain two adjacent O or S atoms. Non-aromatic heterocyclic groups include groups having only 4 atoms in their ring system, but aromatic heterocyclic groups must have at least 5 atoms in their ring system. The heterocyclic groups include benzo-fused ring systems. An example of a 4 membered heterocyclic group is azetidyl (derived from azetidine). An example of a 5 membered heterocyclic group is thiazolyl and an example of a 10 membered heterocyclic group is quinolinyl. Examples of non-aromatic heterocyclic groups are pyrrolidinyl, tetrahydrofuranyl, dihydrofuranyl, tetrahydrothienyl, tetrahydropyranyl, dihydropyranyl, tetrahydrothiopyranyl, piperidino, morpholino, thiomorpholino, thioxanyl, piperazinyl, azetidyl, oxetanyl, thietanyl, homopiperidinyl, oxepanyl, thiepanyl, oxazepinyl, diazepinyl, thiazepinyl, 1,2,3,6-tetrahydropyridinyl, 2-pyrrolinyl, 3-pyrrolinyl, indolinyl, 2H-pyranyl, 4H-pyranyl, dioxanyl, 1,3-dioxolanyl, pyrazolinyl, dithianyl, dithiolanyl, dihydropyranyl, dihydrothienyl, dihydrofuranyl, pyrazolidinyl, imidazolinyl, imidazolidinyl, 3-azabicyclo[3.1.0]hexanyl, 3-azabicyclo[4.1.0]heptanyl, 3H-indolyl and quinoliziny. Examples of aromatic heterocyclic groups are pyridinyl, imidazolyl, pyrimidinyl, pyrazolyl, triazolyl, pyrazinyl, tetrazolyl, furyl, thienyl, isoxazolyl, thiazolyl, oxazolyl, isothiazolyl, pyrrolyl, quinolinyl, isoquinolinyl, indolyl, benzimidazolyl, benzofuranyl, cinnolinyl, indazolyl, indoliziny, phthalazinyl, pyridazinyl, triazinyl, isoindolyl, pteridinyl, purinyl, oxadiazolyl, thiadiazolyl, furazanyl, benzofurazanyl, benzothiofenyl, benzothiazolyl, benzoxazolyl, quinazolinyl, quinoxalinyl, naphthyridinyl, and furopyridinyl. The foregoing groups, as derived from the groups listed above, may be C-attached or N-attached where such is possible. For instance, a group derived from pyrrole may be pyrrol-1-yl (N-attached) or pyrrol-3-yl (C-attached). Further, a group derived from imidazole may be imidazol-1-yl (N-attached) or imidazol-3-yl (C-attached). An example of a heterocyclic group wherein 2 ring carbon atoms are substituted with oxo (=O) moieties is 1,1-dioxo-thiomorpholinyl.

[0029] The phrase "pharmaceutically acceptable salt(s)", as used herein, unless otherwise indicated, includes salts of acidic or basic groups which may be present in the compounds of formula 1. The compounds of formula 1 that are basic in nature are capable of forming a wide variety of salts with various inorganic and organic acids. The acids that may be used to prepare pharmaceutically acceptable acid addition salts of such basic compounds of formula 1 are those that form non-toxic acid addition salts, i.e., salts containing pharmacologically acceptable anions such as the acetate, benzenesulfonate, benzoate, bicarbonate, bisulfate, bitartrate, borate, bromide, calcium edetate, camsylate, carbonate, chloride, clavulanate, citrate, dihydrochloride edetate, edisylate, estolate, esylate, ethylsuccinate, fumarate, gluceptate, gluconate, glutamate, glycolylarsanilate, hexylresorcinate, hydrabamine, hydrobromide, hydrochloride, iodide isothionate, lactate, lactobionate, laurate, malate, maleate, mandelate, mesylate, methylsulfate, mucate, napsylate, nitrate, oleate, oxalate, pamoate (embonate), palmitate, pantothenate, phosphate/diphosphate, polygalacturonate, salicylate, stearate, subacetate, succinate, tannate tartrate, teoclate, tosylate, tethiodode, and valerate salts.


[0030] In the compounds of formula 1, where terms such as $(CR^1R^2)_q$ or $(CR^1R^2)_1$ are used, R^1 and R^2 may vary


with each iteration of q or t above 1. For instance, where q or t is 2 the terms $(CR^1R^2)_q$ or $(CR^1R^2)_t$ may equal $-CH_2CH_2-$ or $-CH(CH_3)C(CH_2CH_3)(CH_2CH_2CH_3)-$, or any number of similar moieties falling within the scope of the definitions of R^1 and R^2 . Further, as noted above, any substituents comprising a CH_3 (methyl), CH_2 (methylene), or CH (methine) group which is not attached to a halogeno, SO or SO_2 group or to a N, O or S atom optionally bears on said group a substituent selected from hydroxy, C_1-C_4 alkoxy and $-NR^1R^2$.

[0031] Certain compounds of formula 1 may have asymmetric centers and therefore exist in different enantiomeric forms. All optical isomers and stereoisomers of the compounds of formula 1, and mixtures thereof, are considered to be within the scope of the invention. With respect to the compounds of formula 1, the invention includes the use of a racemate, one or more enantiomeric forms, one or more diastereomeric forms, or mixtures thereof. The compounds of formula 1 may also exist as tautomers. This invention relates to the use of all such tautomers and mixtures thereof.


[0032] The subject invention also includes isotopically-labelled compounds, which are identical to those recited in Formula 1, but for the fact that one or more atoms are replaced by an atom having an atomic mass or mass number different from the atomic mass or mass number usually found in nature. Examples of isotopes that can be incorporated into compounds of the invention include isotopes of hydrogen, carbon, nitrogen, oxygen, phosphorous, fluorine and chlorine, such as 2H , 3H , ^{13}C , ^{14}C , ^{15}N , ^{18}O , ^{17}O , ^{31}P , ^{32}P , ^{35}S , ^{18}F , and ^{36}Cl , respectively. Compounds of the present invention, prodrugs thereof, and pharmaceutically acceptable salts of said compounds or of said prodrugs which contain the aforementioned isotopes and/or other isotopes of other atoms are within the scope of this invention. Certain isotopically-labelled compounds of the present invention, for example those into which radioactive isotopes such as 3H and ^{14}C are incorporated, are useful in drug and/or substrate tissue distribution assays. Tritiated, i.e., 3H , and carbon-14, i.e., ^{14}C , isotopes are particularly preferred for their ease of preparation and detectability. Further, substitution with heavier isotopes such as deuterium, i.e., 2H , can afford certain therapeutic advantages resulting from greater metabolic stability, for example increased *in vivo* half-life or reduced dosage requirements and, hence, may be preferred in some circumstances. Isotopically labelled compounds of Formula 1 of this invention and prodrugs thereof can generally be prepared by carrying out the procedures disclosed in the Schemes and/or in the Examples and Preparations below, by substituting a readily available isotopically labelled reagent for a non-isotopically labelled reagent.

SCHEME 1



SCHEME 2

SCHEME 3



Detailed Description Of The Invention

[0033] General synthetic methods which may be referred to for preparing the compounds of the present invention are provided in United States patent 5,747,498 (issued May 5, 1998). United States patent application serial number 08/953078 (filed October 17, 1997), WO 98/02434 (published January 22, 1998), WO 98/02438 (published January 22, 1998), WO 96/40142 (published December 19, 1996), WO 96/09294 (published March 6, 1996), WO 97/03069 (published January 30, 1997), WO 95/19774 (published July 27, 1995) and WO 97/13771 (published April 17, 1997). The foregoing patents and patent applications are incorporated herein by reference in their entirety. Certain starting materials may be prepared according to methods familiar to those skilled in the art and certain synthetic modifications may be done according to methods familiar to those skilled in the art. A standard procedure for preparing 6-iodoquinazolinone is provided in Stevenson, T. M., Kazmierczak, F., Leonard, N. J., J. Org. Chem. 1986, 51, 5, p. 616. Palladium-catalyzed boronic acid couplings are described in Miyaura, N., Yanagi, T., Suzuki, A. Syn. Comm. 1981, 11, 7, p. 513. Reduction of aromatic nitro groups can be performed by methods outlined in Brown, R. K., Nelson, N. A. J. Org. Chem. 1954, p. 5149; Yuste, R., Saldana, M, Walls, F., Tet. Lett. 1982, 23, 2, p. 147; or in WO/9609294, referred to above. Nitro substituted N1-phenylsulfonylindoles/indazoles can be prepared by the methods found in Sundberg, R. J., Bloom, J. D., J. Org. Chem. 1980, 45, 17, p. 3382; Ottoni, O. et al. Tetrahedron, 1998, 54, 13915; or Boger, Dale L. et. al.; J. Org. Chem; 55; 4; 1990; 1379.. Substituted nitro N1-benzylindoles/indazoles can be prepared by methods found in Makosza, M.; Owczarczyk, Z.; J Org.Chem., 54, 21, 1989, 5094; Adebayo, Adelaide T O. M., Bowman, W. Russell, Salt, W. G., J. Chem. Soc. Perkin Trans.1, 1989, 1415; or WO 98/02434, referred to above. Benzyloxy-nitrobenzene intermediates may be prepared by methods found in WO 98/02434, referred to above.

[0034] Alternatively, arylmethoxy, or aryloxy nitrobenzene derivatives may be prepared from halo nitrobenzene precursors by nucleophilic displacement of the halide with an appropriate alcohol as described in Dinsmore, C.J. et. al., Bioorg. Med. Chem. Lett., 7, 10, 1997, 1345; or Loupy, A. et. al., Synth. Commun., 20, 18, 1990, 2855; or Brunelle, D. J. Tet. Lett., 25, 32, 1984, 3383. Fused and bridged bicyclic amines were synthesized according to the methods described in: Brighty, K. E. and Castaldi, M. J., Synlett, 1996, 1097; and Momose, T. et al., J. Chem. Soc Perkin Trans. 1, 1997, 1307. Spirocyclic amines were synthesized according to methods found in WO 92/22550. Starting materials,

the synthesis of which is not specifically described herein or the published references referred to above, are either commercially available or can be prepared using methods well known to those of skill in the art.

[0035] In each of the reactions discussed or illustrated in the Schemes above, pressure is not critical unless otherwise indicated. Pressures from about 0.5 atmospheres to about 5 atmospheres are generally acceptable, and ambient pressure, i.e., about 1 atmosphere, is preferred as a matter of convenience.

[0036] Where the compound of formula 6, HNR^1R^3 , is an optionally substituted indole or indoline moiety, such compounds may be prepared according to one or more methods known to those skilled in the art. Such methods are described in PCT international patent application publication number WO 95/23141 and in W.C. Sumpter and F.M. Miller, "Heterocyclic Compounds with Indole and Carbazole Systems," in volume 8 of "The Chemistry of Heterocyclic Compounds", Interscience Publishers Inc., New York (1954). Optional substituents may be included as appropriate before or after the coupling step illustrated in Scheme 1. Prior to the coupling step, primary and secondary amino moieties (other than said amine of formula 6, HNR^1R^3) are preferably protected using a nitrogen protecting group known to those skilled in the art. Such protecting groups and their use are described in T.W. Greene and P.G.M. Wuts, "Protective Groups in Organic Synthesis," Second Edition, John Wiley & Sons, New York, 1991.

[0037] With reference to Scheme 1 above, the compound of formula 1 may be prepared by coupling the compound of formula 5, wherein X, A, and R^4 are as defined above and Z is a leaving group, such as a phenoxy or a phenoxy derivative substituted with halo, cyano, nitro, or lower alkyl, with an amine of the formula 6, HNR^1R^3 , wherein R^1 and R^3 are as defined above, in an anhydrous solvent, in particular a solvent selected from DMF (N,N-dimethylformamide), DME (ethylene glycol dimethyl ether), DCE (dichloroethane), t-butanol, and phenol, or a mixture of the foregoing solvents, at a temperature within the range of about 50-150°C for a period ranging from 1 to 48 hours. The compound of formula 6, HNR^1R^3 , may be prepared by methods known to those skilled in the art, such as reduction of nitriles, reduction of imines or enamines, reduction of oximes, primary and secondary amides, reduction of a nitro group or reductive amination of either R^1NH_2 and $\text{R}^3\text{CH}(\text{O})$ or R^3NH_2 and $\text{R}^1\text{CH}(\text{O})$. The compound of formula 5 may be prepared by treating a compound of formula 4, wherein Z^2 is $-(\text{CR}^1\text{R}^2)_t(\text{C}_6\text{-C}_{10} \text{ aryl})$ or $-(\text{CR}^1\text{R}^2)_t(4\text{-}10 \text{ membered heterocyclic})$, wherein t, R^1 and R^2 are as defined above as provided in the definition of R^4 , and the aryl and heterocyclic groups of the foregoing groups are substituted by a group that includes an aldehyde or acid moiety that may be modified to introduce one or more groups selected from $-(\text{CR}^1\text{R}^2)_q\text{NR}^9$, $-(\text{CR}^1\text{R}^2)_q\text{NR}^9(\text{C}_1\text{-C}_6 \text{ alkanoyl})$, $-(\text{CR}^1\text{R}^2)_q\text{OR}^9$, and $-(\text{CR}^1\text{R}^2)_q\text{R}^9$ as provided in the definition of R^4 above. Such modifications may be done according to methods familiar to those skilled in the art. For instance, an amine moiety may be introduced by reductive amination of an aldehyde group. A compound of the formula 4 can be obtained by treating a compound of the formula 3, wherein Z^1 is an activating group, such as bromo, iodo, $-\text{N}_2$, or $-\text{OTf}$ (which is $-\text{OSO}_2\text{CF}_3$), with a coupling partner of the formula $\text{X}^1-(\text{CR}^1\text{R}^2)_t(\text{C}_6\text{-C}_{10} \text{ aryl})$ or $\text{X}^1-(\text{CR}^1\text{R}^2)_t(4\text{-}10 \text{ membered heterocyclic})$, wherein t, R^1 and R^2 are as defined above as provided in the definition of R^4 , the aryl and heterocyclic groups of the foregoing groups are substituted with a group that includes an aldehyde or acid moiety, and X^1 is $-\text{B}(\text{OH})_2$ or $-\text{Sn}(\text{C}_1\text{-C}_5 \text{ alkyl})_3$. This reaction is generally done using palladium (0) or palladium (II) catalysts in a solvent such as DMF, THF (tetrahydrofuran), toluene, dioxanes, or a mixture of the foregoing solvents, at 60-100°C for about 8-24 hours. The compound of formula 2 may be converted to the compound of formula 3 wherein Z is a substituted phenoxy derivative by treating the starting compound with an appropriate metal phenoxide, such as sodium phenolate, in a solvent, such as DMF or phenol, at a temperature ranging from about 0°C to 100°C for a period ranging from about 2 to 24 hours.

[0038] In the alternative, compounds of the formula 1 may be prepared according to the synthesis outlined in Scheme 2. In Scheme 2, a compound of the formula 1 may be obtained by treating a compound of formula 8, wherein Z^2 is as defined above, as described above regarding the conversion of the compound of formula 4 to a compound of formula 5. A compound of the formula 8 may be obtained by treating a compound of formula 7, wherein Z^1 is an activating group as defined above, as described above regarding the conversion of the compound of formula 3 to a compound of formula 4. A compound of formula 7 may be obtained from a compound of formula 2 by reaction with an amine of the formula 6, HNR^1R^3 , wherein R^1 and R^3 are as defined above, in an anhydrous solvent, in particular a solvent selected from DMF, DME, DCE, t-butanol, and phenol, or a mixture of the foregoing solvents, at a temperature within the range of about 50-150°C for a period ranging from about 1 to 48 hours.

[0039] The starting compound of formula 2 may be prepared as illustrated in Scheme 3. In Scheme 3, the compound of formula 11 wherein X is NH may be prepared from a compound of formula 9, wherein A and Z^1 are as defined above and Z^3 is OH, according to one or more procedures described in WO 95/19774, referred to above, and a compound of formula 11 wherein X is CH may be prepared from a compound of formula 10, wherein A and Z^1 are as defined above, according to procedures described in WO 95/19774, referred to above. The compound of formula 11 may be converted to the compound of formula 2 by treating the starting compound with a chlorinating reagent, such as POCl_3 or $\text{ClC}(\text{O})\text{C}(\text{O})\text{Cl}/\text{DMF}$ in a halogenated solvent at a temperature ranging from about 60°C to 150°C for a period ranging from about 2 to 24 hours.

[0040] The compounds of the present invention may have asymmetric carbon atoms. Diastereomeric mixtures can be separated into their individual diastereomers on the basis of their physical chemical differences by methods known to

those skilled in the art, for example, by chromatography or fractional crystallization. Enantiomers can be separated by converting the enantiomeric mixtures into a diastereomeric mixture by reaction with an appropriate optically active compound (e.g., alcohol), separating the diastereomers and converting (e.g., hydrolyzing) the individual diastereomers to the corresponding pure enantiomers. All such isomers, including diastereomeric mixtures and pure enantiomers are considered as part of the invention.

[0041] The compounds of formulas 1 that are basic in nature are capable of forming a wide variety of different salts with various inorganic and organic acids. Although such salts must be pharmaceutically acceptable for administration to animals, it is often desirable in practice to initially isolate the compound of formula 1 from the reaction mixture as a pharmaceutically unacceptable salt and then simply convert the latter back to the free base compound by treatment with an alkaline reagent and subsequently convert the latter free base to a pharmaceutically acceptable acid addition salt. The acid addition salts of the base compounds of this invention are readily prepared by treating the base compound with a substantially equivalent amount of the chosen mineral or organic acid in an aqueous solvent medium or in a suitable organic solvent, such as methanol or ethanol. Upon careful evaporation of the solvent, the desired solid salt is readily obtained. The desired acid salt can also be precipitated from a solution of the free base in an organic solvent by adding to the solution an appropriate mineral or organic acid.

[0042] Those compounds of formula 1 that are acidic in nature are capable of forming base salts with various pharmacologically acceptable cations. Examples of such salts include the alkali metal or alkaline-earth metal salts and particularly, the sodium and potassium salts. These salts are all prepared by conventional techniques. The chemical bases which are used as reagents to prepare the pharmaceutically acceptable base salts of this invention are those which form non-toxic base salts with the acidic compounds of formula 1. Such non-toxic base salts include those derived from such pharmacologically acceptable cations as sodium, potassium calcium and magnesium, etc. These salts can easily be prepared by treating the corresponding acidic compounds with an aqueous solution containing the desired pharmacologically acceptable cations, and then evaporating the resulting solution to dryness, preferably under reduced pressure. Alternatively, they may also be prepared by mixing lower alkanolic solutions of the acidic compounds and the desired alkali metal alkoxide together, and then evaporating the resulting solution to dryness in the same manner as before. In either case, stoichiometric quantities of reagents are preferably employed in order to ensure completeness of reaction and maximum yields of the desired final product.

[0043] The compounds of the present invention are potent inhibitors of the erbB family of oncogenic and protooncogenic protein tyrosine kinases such as epidermal growth factor receptor (EGFR), *erbB2*, *HER3*, or *HER4* and thus are all adapted to therapeutic use as antiproliferative agents (e.g., anticancer) in mammals, particularly in humans. In particular, the compounds of the present invention are useful in the prevention and treatment of a variety of human hyperproliferative disorders such as malignant and benign tumors of the liver, kidney, bladder, breast, gastric, ovarian, colorectal, prostate, pancreatic, lung, vulval, thyroid, hepatic carcinomas, sarcomas, glioblastomas, head and neck, and other hyperplastic conditions such as benign hyperplasia of the skin (e.g., psoriasis) and benign hyperplasia of the prostate (e.g., BPH). It is, in addition, expected that a compound of the present invention may possess activity against a range of leukemias and lymphoid malignancies.

[0044] The compounds of the present invention may also be useful in the treatment of additional disorders in which aberrant expression ligand/receptor interactions or activation or signalling events related to various protein tyrosine kinases, are involved. Such disorders may include those of neuronal, glial, astrocytic, hypothalamic, and other glandular, macrophagal, epithelial, stromal, and blastocoelic nature in which aberrant function, expression, activation or signalling of the erbB tyrosine kinases are involved. In addition, the compounds of the present invention may have therapeutic utility in inflammatory, angiogenic and immunologic disorders involving both identified and as yet unidentified tyrosine kinases that are inhibited by the compounds of the present invention.

[0045] The *in vitro* activity of the compounds of formula 1 may be determined by the following procedure.

[0046] The c-erbB2 kinase assay is similar to that described previously in Schrang et. al., Anal. Biochem. 211, 1993, p233-239. Nunc MaxiSorp 96-well plates are coated by incubation overnight at 37°C with 100 µL per well of 0.25 mg/mL Poly (Glu, Tyr) 4:1 (PGT) (Sigma Chemical Co., St. Louis, MO) in PBS (phosphate buffered saline). Excess PGT is removed by aspiration, and the plate is washed three times with wash buffer (0.1% Tween 20 in PBS). The kinase reaction is performed in 50 µL of 50 mM HEPES (pH 7.5) containing 125 mM sodium chloride, 10 mM magnesium chloride, 0.1 mM sodium orthovanadate, 1 mM ATP, 0.48 mg/mL (24 ng/well) c-erbB2 intracellular domain. The intracellular domain of the erbB2 tyrosine kinase (amino acids 674-1255) is expressed as a GST fusion protein in Baculovirus and purified by binding to and elution from glutathione coated beads. The compound in DMSO (dimethylsulfoxide) is added to give a final DMSO concentration of about 2.5%. Phosphorylation was initiated by addition of ATP (adenosine triphosphate) and proceeded for 6 minutes at room temperature, with constant shaking. The kinase reaction is terminated by aspiration of the reaction mixture and subsequent washing with wash buffer (see above). Phosphorylated PGT is measured by 25 minutes of incubation with 50 µL per well HRP-conjugated PY54 (Oncogene Science Inc. Uniondale, NY) antiphosphotyrosine antibody, diluted to 0.2 mg/mL in blocking buffer (3% BSA and 0.05% Tween 20 in PBS). Antibody is removed by aspiration, and the plate is washed 4 times with wash buffer. The colorimetric signal

is developed by addition of TMB Microwell Peroxidase Substrate (Kirkegaard and Perry, Gaithersburg, MD), 50 mL per well, and stopped by the addition of 0.09 M sulfuric acid, 50 mL per well. Phosphotyrosine is estimated by measurement of absorbance at 450 nm. The signal for controls is typically 0.6-1.2 absorbance units, with essentially no background in wells without the PGT substrate and is proportional to the time of incubation for 10 minutes. Inhibitors were identified by reduction of signal relative to wells without inhibitor and IC_{50} values corresponding to the concentration of compound required for 50% inhibition are determined.

[0047] The activity of the compounds of formula 1, *in vivo*, can be determined by the amount of inhibition of tumor growth by a test compound relative to a control. The tumor growth inhibitory effects of various compounds are measured according to the method of Corbett T.H., et al, "Tumor Induction Relationships in Development of Transplantable Cancers of the Colon in Mice for Chemotherapy Assays, with a Note on Carcinogen Structure", *Cancer Res.*, 35, 2434-2439 (1975) and Corbett T.H., et al., "A Mouse Colon-tumor Model for Experimental Therapy", *Cancer Chemother. Rep. (Part 2)*", 5, 169-186 (1975), with slight modifications. Tumors are induced in the left flank by subcutaneous (sc) injection of 1-5 million log phase cultured tumor cells (murine FRE-ErbB2 cells or human SK-OV3 ovarian carcinoma cells) suspended in 0.1 ml RPMI 1640 medium. After sufficient time has elapsed for the tumors to become palpable (100-150 mm³ in size/5-6 mm in diameter) the test animals (athymic female mice) are treated with test compound (formulated at a concentration of 10 to 15 mg/ml in 5 Gelucire) by the intraperitoneal (ip) or oral (po) route of administration once or twice daily for 7 to 10 consecutive days. In order to determine an anti-tumor effect, the tumor is measured in millimeters with a Vernier caliper across two diameters and the tumor size (mm³) is calculated using the formula: Tumor size (mm³) = (length \pm [width]²)/2, according to the methods of Geran, R.I., et al. "Protocols for Screening Chemical Agents and Natural Products Against Animal Tumors and Other Biological Systems", Third Edition, *Cancer Chemother. Rep.*, 3, 1-104 (1972). Results are expressed as percent inhibition, according to the formula: Inhibition (%) = $(TuW_{control} - TuW_{test})/TuW_{control} \times 100\%$. The flank site of tumor implantation provides reproducible dose/response effects for a variety of chemotherapeutic agents, and the method of measurement (tumor diameter) is a reliable method for assessing tumor growth rates.

[0048] Administration of the compounds of the present invention (hereinafter the "active compound(s)") can be effected by any method that enables delivery of the compounds to the site of action. These methods include oral routes, intraduodenal routes, parenteral injection (including intravenous, subcutaneous, intramuscular, intravascular or infusion), topical, and rectal administration.

[0049] The amount of the active compound administered will be dependent on the subject being treated, the severity of the disorder or condition, the rate of administration, the disposition of the compound and the discretion of the prescribing physician. However, an effective dosage is in the range of about 0.001 to about 100 mg per kg body weight per day, preferably about 1 to about 35 mg/kg/day, in single or divided doses. For a 70 kg human, this would amount to about 0.05 to about 7 g/day, preferably about 0.2 to about 2.5 g/day. In some instances, dosage levels below the lower limit of the aforesaid range may be more than adequate, while in other cases still larger doses may be employed without causing any harmful side effect, provided that such larger doses are first divided into several small doses for administration throughout the day.

[0050] The active compound may be applied as a sole therapy or may involve one or more other anti-tumour substances, for example those selected from, for example, mitotic inhibitors, for example vinblastine; alkylating agents, for example cis-platin, carboplatin and cyclophosphamide; anti-metabolites, for example 5-fluorouracil, cytosine arabinoside and hydroxyurea, or, for example, one of the preferred anti-metabolites disclosed in European Patent Application No. 239362 such as *N*-(5-[*N*-(3,4-dihydro-2-methyl-4-oxoquinazolin-6-ylmethyl)-*N*-methylamino]-2-thenoyl)-L-glutamic acid; growth factor inhibitors; cell cycle inhibitors; intercalating antibiotics, for example adriamycin and bleomycin; enzymes, for example interferon; and anti-hormones, for example anti-estrogens such as NolvadexTM (tamoxifen) or, for example anti-androgens such as CasodexTM (4'-cyano-3-(4-fluorophenylsulphonyl)-2-hydroxy-2-methyl-3'-(trifluoromethyl)propionanilide). Such conjoint treatment may be achieved by way of the simultaneous, sequential or separate dosing of the individual components of the treatment.

[0051] The pharmaceutical composition may, for example, be in a form suitable for oral administration as a tablet, capsule, pill, powder, sustained release formulations, solution, suspension, for parenteral injection as a sterile solution, suspension or emulsion, for topical administration as an ointment or cream or for rectal administration as a suppository. The pharmaceutical composition may be in unit dosage forms suitable for single administration of precise dosages. The pharmaceutical composition will include a conventional pharmaceutical carrier or excipient and a compound according to the invention as an active ingredient. In addition, it may include other medicinal or pharmaceutical agents, carriers, adjuvants, etc.

[0052] Exemplary parenteral administration forms include solutions or suspensions of active compounds in sterile aqueous solutions, for example, aqueous propylene glycol or dextrose solutions. Such dosage forms can be suitably buffered, if desired.

[0053] Suitable pharmaceutical carriers include inert diluents or fillers, water and various organic solvents. The pharmaceutical compositions may, if desired, contain additional ingredients such as flavorings, binders, excipients and the

like. Thus for oral administration, tablets containing various excipients, such as citric acid may be employed together with various disintegrants such as starch, alginic acid and certain complex silicates and with binding agents such as sucrose, gelatin and acacia. Additionally, lubricating agents such as magnesium stearate, sodium lauryl sulfate and talc are often useful for tableting purposes. Solid compositions of a similar type may also be employed in soft and hard filled gelatin capsules. Preferred materials, therefor, include lactose or milk sugar and high molecular weight polyethylene glycols. When aqueous suspensions or elixirs are desired for oral administration the active compound therein may be combined with various sweetening or flavoring agents, coloring matters or dyes and, if desired, emulsifying agents or suspending agents, together with diluents such as water, ethanol, propylene glycol, glycerin, or combinations thereof.

[0054] Methods of preparing various pharmaceutical compositions with a specific amount of active compound are known, or will be apparent, to those skilled in this art. For examples, see Remington's Pharmaceutical Sciences, Mack Publishing Company, Easter, Pa., 15th Edition (1975).

[0055] The examples and preparations provided below further illustrate and exemplify the compounds of the present invention and methods of preparing such compounds. It is to be understood that the scope of the present invention is not limited in any way by the scope of the following examples and preparations. In the following examples, "Ac" means acetyl, "Et" means ethyl, "Me" means methyl, and "Bu" means butyl.

[0056] Where HPLC chromatography is referred to in the preparations and examples below, the general conditions used, unless otherwise indicated, are as follows. The column used is a ZORBAX™ RXC18 column (manufactured by Hewlett Packard) of 150 mm distance and 4.6 mm interior diameter. The samples are run on a Hewlett Packard- 1100 systemA gradient solvent method is used running 100 percent ammonium acetate / acetic acid buffer (0.2 M) to 100 percent acetonitrile over 10 minutes. The system then proceeds on a wash cycle with 100 percent acetonitrile for 1.5 minutes and then 100 percent buffer solution for 3 minutes. The flow rate over this period is a constant 3 ml / minute.

Method A: Synthesis of (3-{4-[4-(1-Cyclopropylmethyl-1H-indol-5-ylamino)-quinazolin-6-yl]-benzyl}-3-azabicyclo[3.1.0]hex-6-yl)-methanol (18)

6-Iodo-4-quinazolinone (12):

[0057] A solution of 2-amino-5-iodobenzoic acid (26.3 g, 100 mmol) and formamidine acetate (13.5 g, 130 mmol) in ethanol (400 mL) was refluxed for 20 hours. After cooling to 0°C, the solid product was collected by filtration. Further drying *in vacuo* provided 6-iodo-4-quinazolinone **12** (22.0 g, 81%) as a grey crystalline solid. ¹H NMR (400 MHz; DMSO-d₆) δ: 12.38 (br. s, 1H), 8.35 (d, 1H), 8.05-8.10 (m, 2H), 7.43 (dd, 1H). LRMS: 272.9 (MH⁺).

6-iodo-4-chloroquinazoline (13):

[0058] To a stirred solution of DMF (N,N-dimethylformamide) (6.3 mL) in DCE (dichloroethane) (20 mL) cooled to 0°C was added dropwise a solution of oxalyl chloride (60 mL of a 2M solution in DCE). After addition was complete, the cooling bath was removed and 6-iodo-3H-quinazolinone **12** (log, 36.8 mmol) was added as a solid. The resulting mixture was heated to reflux under nitrogen for 3 hours. Upon cooling to room temperature, the reaction was quenched cautiously with H₂O. CH₂Cl₂ was added and the bilayer transferred to a separatory funnel. The aqueous layer was extracted with CH₂Cl₂ (2x50 mL) and the combined organic layers dried (Na₂SO₄). The solvent was removed *in vacuo* to provide a yellow solid which was triturated with diethyl ether to remove any remaining impurities. The resulting yellow solid obtained by filtration was shown to be pure by NMR. For compound **13**: ¹H NMR (CDCl₃, 400 MHz) δ: 9.05 (s, 1H), 8.65 (d, 1H), 8.21 (dd, 1H), 7.78 (d, 1H).

6-iodo-4-phenoxyquinazoline (14):

[0059] A suspension of NaH (washed free of mineral oil) in DMF (40 mL) was cooled to 0°C and a solution of phenol (5.65 g, 60 mmol) in DMF (20 mL) was added dropwise. Upon completion of addition, 6-iodo-4-chloroquinazoline **13** (14.6 g, 50.3 mmol) was added as a solid in small portions. The cooling bath was moved and the reaction mixture was stirred at room temperature for 2 hours. The mixture was then quenched with water (200 mL), diluted with EtOAc (300 mL) and transferred to a separatory funnel. The organic layer was washed with dilute aqueous NaOH, water and brine and dried over Na₂SO₄. Filtration of the solids and removal of the solvent provided 6-iodo-4-phenoxyquinazoline **14** (17.2 g, 98%) as a yellow solid. ¹H NMR (400 MHz; CDCl₃) δ: 8.74 (d, 1H), 8.14 (s, 1H), 8.12 (dd, 1H), 7.71 (d, 1H), 7.49 (dd, 2H), 7.32 (t, 1H), 7.22 (m, 2H).

4-(4-Phenoxy-quinazolin-6-yl)benzaldehyde (15):

[0060] To a solution of toluene (211 mL) in a 1.0 L round-bottom flask equipped with a reflux condenser was added 1,4-bis(diphenyl)phosphino)-butane (1.22 g, 2.87 mmol) and bis(benzonitrile)dichloro-palladium (1.1 g, 2.87 mmol). The resulting solution was stirred at room temperature for 30 minutes followed by the addition of THF (tetrahydrofuran) (255 mL) and EtOH (115 mL). To the resulting mixture was added 6-iodo-4-phenoxy-quinazoline **14** (5.0 g, 14.4 mmol), 4-formylphenylboronic acid (4.3 g, 28.7 mmol) and aqueous 1M Na₂CO₃ (29 mL). The mixture was heated at reflux under an atmosphere of N₂ for 18 hours. The reaction mixture was filtered hot and the solvent removed under reduced pressure. The residue was taken up in CHCl₃ and washed with water, brine, and dried (MgSO₄). The solvent was removed under reduced pressure and the residue was purified using flash chromatography (silica gel, EtOAc/hexanes 4:6) to provide (4.42 g, 13.54 mmol) 4-(4-phenoxy-quinazolin-6-yl)benzaldehyde **15** in 94% yield. ¹H NMR (CDCl₃) δ 7.26 (m, 3H), 2.88 (m, 1H), 7.51 (m, 2H), 7.92 (d, 2H, *J* = 8.4 Hz), 8.02 (d, 2H, *J* = 8 Hz), 8.11 (d, 1H, *J* = 8.8 Hz), 8.20 (dd, 1H, *J* = 2.4 and 8.8 Hz), 8.63 (d, 1H, *J* = 2.4 Hz), 8.79 (s, 1H); MS (CI) *m/e* 326 (*M*⁺ + 1, 100).

3-[4-(4-Phenoxy-quinazolin-6-yl)-benzyl]-3-aza-bicyclo[3.1.0]hex-6-yl]-methanol (16):

[0061] To a solution of 1:1 CHCl₃ and MeOH in a round-bottom flask under N₂ was added (3-aza-bicyclo[3.1.0]hex-6-yl)-methanol **17** (2.27 g, 19.7 mmol) which was allowed to stir at room temperature for fifteen minutes. To the amine solution was added 4-(4-phenoxy-quinazolin-6-yl)benzaldehyde **15** (3.78 g, 11.6 mmol) followed by the dropwise addition of acetic acid until the pH was approximately 6. NaCNBH₃ was added to the reaction mixture which was then allowed to stir overnight at room temperature under an atmosphere of N₂. The solution was diluted with CHCl₃ and washed 3x with aqueous NaHCO₃ until the pH was approximately 9. The organic layer was separated, dried (MgSO₄) and removed under reduced pressure to provide a yellow viscous oil. The residue was purified by flash chromatography (silica gel, EtOAc-5%MeOH/EtOAc) to provide (3.51 g, 8.28 mmol) compound **16** as a white solid in 71% yield. For compound **16**: ¹H NMR (CDCl₃) δ 8.75 (s, 1H), 8.54 (d, 1H *J* = 2 Hz), 8.17 (dd, 1H *J* = 8.4 and 2.4 Hz), 8.05 (d, 1H, *J* = 8.4 Hz), 7.66 (d, 2H, *J* = 8 Hz), 7.48 (m, 2H), 7.39 (m, 2H), 7.32 (m, 1H), 7.25 (m, 2H), 3.65 (s, 2H), 3.44 (d, 2H, *J* = 3.6 Hz), 3.02 (d, 2H, *J* = 8.8 Hz), 2.38 (d, 2H, *J* = 8.4 Hz), 1.62 (m, 1H), 1.30 (s, 2H); MS (CI) *m/e* 423 (*M*⁺ + 1, 100).

(3-[4-[4-(1-Cyclopropylmethyl-1H-Indol-5-ylamino)-quinazolin-6-yl]-benzyl]-3-aza-bicyclo[3.1.0]hex-6-yl]-methanol (18):

[0062] To a 3 mL Wheaton vial was added (3-[4-(4-phenoxy-quinazolin-6-yl)-benzyl]-3-aza-bicyclo[3.1.0]hex-6-yl)-methanol **16** (100 mg, 0.24 mmol), 1-cyclopropylmethyl-1H-indol-5-ylamine **19** (48 mg, 0.26 mmol), pyridinium hydrochloride (33 mg, 0.284 mmol), and phenol (155 mg, 1.652 mmol). The vial was capped and heated overnight at 110°C. The vial was cooled to room temperature and the residue taken up in CHCl₃ and washed with 15% aqueous NaOH, water, brine, and dried (MgSO₄). The solvent was removed and the residue purified by flash chromatography (silica gel, EtOAc:MeOH, 95:5) to provide compound **18** (88 mg, 0.159 mmol) as a light brown solid in 67% yield. For compound **18**: MS (CI) *m/e* 515 (*M*⁺ + 1, 100); HPLC, *rt* = 4.83 min.

Method B: Synthesis of 8-[4-[4-(1-Benzenesulfonyl-1H-Indol-5-ylamino)-quinazolin-6-yl]-benzyl]-8-aza-bicyclo[3.2.1]octan-3-ol

[0063] **{1-Benzenesulfonyl-1H-indol-5-yl)-(6-iodo-quinazolin-4-yl)-amine (20):** 6-iodo-4-chloroquinazoline **13** (2.38 g, 8.20 mmol) and 5-amino-1-benzenesulfonylindole **21** (2.46 g, 9.00 mmol) were combined in DCE (20 mL) and t-butanol (20 mL). The resulting mixture was heated at reflux under nitrogen for 18 hours to form a bright yellow suspension. Upon cooling the solids were filtered and rinsed with CH₂Cl₂ and placed under high vacuum to remove any excess solvent. The title compound (3.23g, 75%) was obtained as a yellow solid. For compound **20**: ¹H NMR (DMSO-d₆, 400 MHz): δ: 10.05 (s, 2H), 8.93 (s, 1H), 8.53 (s, 1H), 8.25 (m, 1H), 8.10 (m, 5H), 7.97 (m, 3H), 7.82 (m, 2H), 7.70 (m, 2H), 7.65 (m, 2H), 6.88 (d, 1H, *J* = 3.57 Hz).

4-[4-{1-Benzenesulfonyl-1H-indol-5-ylamino)-quinazolin-6-yl]-benzaldehyde (22):

[0064] To a solution of toluene (100 mL) in a 500 mL round-bottom flask equipped with a reflux condenser was added 1,4-bis(diphenyl)phosphino)-butane (4.25 mg, 0.997 mmol) and bis(benzonitrile)dichloro-palladium (385 g, 0.997 mmol). Nitrogen was bubbled through the reaction mixture for 1 minute and the resulting suspension was stirred at room temperature for 30 minutes. THF (125 mL) and EtOH (50 mL) were then added. To the resulting mixture was added (1-benzenesulfonyl-1H-indol-5-yl)-(6-iodo-quinazolin-4-yl)-amine **20** (3.5 g, 6.6 mmol), 4-formylphenylboronic acid (1.99 g, 13.3 mmol) and 2M aq Na₂CO₃ (6.7 mL). The mixture was heated at reflux under an atmosphere of N₂

for 15 hours. The solvent was removed under reduced pressure and the residue was purified using flash chromatography (silica gel, EtOAc/hexanes 1:1) to provide 3.1 g of 4-[4-(1-benzenesulfonyl-1H-indol-5-ylamino)-quinazolin-6-yl]-benzaldehyde **22** in 92% yield. ¹H NMR (DMSO-d₆; 400 MHz): δ: 9.24 (s, 1H, NH), 8.84 (s, 1H), 8.33 (dd, 1H, J=8.9 Hz and 1.7 Hz), 8.01 (m, 4H), 7.90 (m, 2H), 7.70 (m, 2H), 7.60 (m, 3H), 6.92 (dd, 1H, J=3.7 Hz and 0.6 Hz); MS (CI) m/e 505.1 (M⁺ + 1, 100).

8-[4-[4-(1-Benzenesulfonyl-1H-indol-5-ylamino)-quinazolin-6-yl]-benzyl]-8-aza-bicyclo[3.2.1]octan-3-ol (23):

[0065] To a solution of CHCl₃ (1.5 mL) and MeOH (3 mL) in a round-bottom flask under N₂ was added 8-aza-bicyclo[3.2.1]octan-3-ol **24** (70 mg, 0.495 mmol). AcOH was added to adjust the pH to 5. To the amine solution was added 4-[4-(1-benzenesulfonyl-1H-indol-5-ylamino)-quinazolin-6-yl]-benzaldehyde **22** (100 mg, 0.198 mmol) and the resulting solution was stirred at room temperature for 3 hours. NaCNBH₃ was added to the reaction mixture which was then allowed to stir overnight at room temperature under an atmosphere of N₂. The solution was diluted with CH₂Cl₂ and poured into 1N NaOH (10 mL). The aqueous layer was separated and extracted with another 2 X 15 mL of CH₂Cl₂. The organic layers were dried (MgSO₄) and the solvent was removed under reduced pressure to provide a yellow viscous oil. The residue was purified by flash chromatography (silica gel, CH₂Cl₂-10%MeOH/CH₂Cl₂) to provide 45 mg of compound **23** as a white solid in 36% yield. HPLC, rt = 5.25 min; MS (CI) m/e 616.2 (M⁺ + 1, 100).

[0066] The following examples were prepared following either method A or method B as described above. In the Table, the term "min" refers to minutes.

TABLE

Example Number	Method of preparation	IUPAC name	LRMS (MH ⁺)	HPLC
1	A	{6-[4-(6-Amino-3-aza-bicyclo[3.1.0]hex-3-ylmethyl)-phenyl]-quinazolin-4-yl}-(1-benzenesulfonyl-1H-indol-5-yl)-amine	587.2	7.99 min
2	A	{6-[4-(6-Amino-3-aza-bicyclo[3.1.0]hex-3-ylmethyl)-phenyl]-quinazolin-4-yl}-(4-benzyl-phenyl)-amine	498.3	5.09 min
3	A	{6-[4-(6-Amino-3-aza-bicyclo[3.1.0]hex-3-ylmethyl)-phenyl]-quinazolin-4-yl}-(4-phenoxy-phenyl)-amine	500.3	4.93 min
4	A	(3-{4-[4-(4-Benzyl-phenylamino)-quinazolin-6-yl]benzyl}-3-aza-bicyclo[3.1.0]hex-6-yl)-methanol	513.2	5.44 min
5	A	(3-{4-[4-(4-Phenoxy-phenylamino)-quinazolin-6-yl]benzyl}-3-aza-bicyclo[3.1.0]hex-6-yl)-methanol	515.4	5.27 min

TABLE (continued)

Example Number	Method of preparation	IUPAC name	LRMS (MH+)	HPLC
6	A	(3-{4-[4-(1-Benzenesulfonyl-1H-indol-5-ylamino)-quinazolin-6-yl]-benzyl}-3-aza-bicyclo[3.1.0]hex-6-yl)-methanol	602.3	5.17 min
7	B	(6-{4-[(1-Aza-bicyclo[2.2.2]oct-3-ylamino)-methyl]-phenyl}-quinazolin-4-yl)-(4-phenoxy-phenyl)-amine	526.4	5.43 min
8	B	(6-{4-[(1-Aza-bicyclo[2.2.2]oct-3-ylamino)-methyl]-phenyl}-quinazolin-4-yl)-(4-benzyl-phenyl)-amine	526.4	5.52 min
9	B	(6-{4-[(1-Aza-bicyclo[2.2.2]oct-3-ylamino)-methyl]-phenyl}-quinazolin-4-yl)-{1-benzenesulfonyl-1H-indol-5-yl}-amine	613.4 (-)	5.33 min
10	B	(6-{4-[(3-Aza-bicyclo[3.1.0]hex-6-ylamino)-methyl]-phenyl}-quinazolin-4-yl)-(4-phenoxy-phenyl)-amine	500.3	4.93 min
11	B	(6-{4-[(3-Aza-bicyclo[3.1.0]hex-6-ylamino)-methyl]-phenyl}-quinazolin-4-yl)-(4-benzyl-phenyl)-amine	498.3	5.10 min
12	B	3-{4-[4-(4-Benzyl-phenylamino)-quinazolin-6-yl]-benzylamino}-8-methyl-8-aza-bicyclo[3.2.1]octan-6-ol	558.3	4.47 min/5.77 min diastereomer
13	B	(6-{4-[(3-Aza-bicyclo[3.1.0]hex-6-ylamino)-methyl]-phenyl}-quinazolin-4-yl)-(1-benzenesulfonyl-1H-indol-5-yl)-amine	587.2	4.80 min

TABLE (continued)

Example Number	Method of preparation	IUPAC name	LRMS (MH+)	HPLC
14	A	(4-Benzyl-phenyl)-{6-[4-(6-methoxymethyl-3-aza-bicyclo[3.1.0]hex-3-ylmethyl)-phenyl]-quinazolin-4-yl}-amine	527.3	6.06 min
15	A	{6-[4-(6-Methoxymethyl-3-aza-bicyclo[3.1.0]hex-3-ylmethyl)-phenyl]-quinazolin-4-yl}-(4-phenoxy-phenyl)-amine	529.4	5.86 min
16	A	(1-Benzenesulfonyl-1H-indol-5-yl)-{6-[4-(6-methoxymethyl-3-aza-bicyclo[3.1.0]hex-3-ylmethyl)-phenyl]-quinazolin-4-yl}-amine	616.2	5.64 min
17	B	(3-{4-[4-(4-Phenoxy-phenylamino)-quinazolin-6-yl]-benzylamino}-bicyclo[2.2.1]hept-2-yl)-methanol	543.3	5.93 min
18	B	(3-{4-[4-(4-Benzyl-phenylamino)-quinazolin-6-yl]-benzylamino}-bicyclo[2.2.1]hept-2-yl)-methanol	541.3	6.15 min
19	B	(3-{4-[4-(1-Benzenesulfonyl-1H-indol-5-ylamino)-quinazolin-6-yl]-benzylamino}-bicyclo[2.2.1]hept-2-yl)-methanol	630.2	5.78 min
20	A	(4-Benzyl-phenyl)-(6-{4-[(8-methyl-8-aza-bicyclo[3.2.1]oct-3-ylamino)-methyl]-phenyl}-quinazolin-4-yl)-amine	540.4	5.97 min
21	A	(6-[4-[(8-Methyl-8-aza-bicyclo[3.2.1]oct-3-ylamino)-methyl]-phenyl]-quinazolin-4-yl)-(4-phenoxy-phenyl)-amine	542.3	5.76 min

TABLE (continued)

Example Number	Method of preparation	IUPAC name	LRMS (MH+)	HPLC
22	A	(1-Benzenesulfonyl-1H-indol-5-yl)-(6-[4-(8-methyl-8-aza-bicyclo[3.2.1]oct-3-ylamino)-methyl]-phenyl)-quinazolin-4-yl)-amine	629.2	5.60 min
23	A	(3-{4-[4-(4-{1,2,3}Thiadiazol-5-yl-phenylamino)-quinazolin-6-yl]-benzyl}-3-aza-bicyclo[3.1.0]hex-6-yl)-methanol	507.3	4.41 min
24	A	(3-{4-[4-(4-Cyclohexyl-phenylamino)-quinazolin-6-yl]-benzyl}-3-aza-bicyclo[3.1.0]hex-6-yl)-methanol	505.4	6.11 min
25	B	8-Methyl-3-{4-[4-(4-phenoxy-phenylamino)-quinazolin-6-yl]-benzylamino}-8-aza-bicyclo[3.2.1]octan-6-ol	558.3	5.64 min
26	B	3-{4-[4-(1-Benzyl-1H-indol-5-ylamino)-quinazolin-6-yl]-benzylamino}-8-methyl-8-aza-bicyclo[3.2.1]octan-6-ol	595.3	5.44 min
27	B	3-{4-[4-(1-Benzenesulfonyl-1H-indol-5-ylamino)-quinazolin-6-yl]-benzylamino}-8-methyl-8-aza-bicyclo[3.2.1]octan-6-ol	645.3	5.53 min
28	A	(3-{4-[4-(4-p-Tolyloxy-phenylamino)-quinazolin-6-yl]-benzyl}-3-aza-bicyclo[3.1.0]hex-6-yl)-methanol	529.4	5.63 min
29	A	(3-{4-[4-(Biphenyl-4-ylamino)-quinazolin-6-yl]-benzyl}-3-aza-bicyclo[3.1.0]hex-6-yl)-methanol	499.3	5.36 min

TABLE (continued)

Example Number	Method of preparation	IUPAC name	LRMS (MH+)	HPLC
30	A	(3-{4-[4-(4-Ethyl-phenylamino)-quinazolin-6-yl]-benzyl}-3-aza-bicyclo[3.1.0]hex-6-yl)-methanol	451.3	4.73 min
31	A	4-{6-[4-(6-Hydroxymethyl-3-aza-bicyclo[3.1.0]hex-3-ylmethyl)-phenyl]-quinazolin-4-ylamino}-N-phenyl-benzamide	542.2	4.30 min
32	A	N,N-Diethyl-3-{6-[4-(6-hydroxymethyl-3-aza-bicyclo[3.1.0]hex-3-ylmethyl)-phenyl]-quinazolin-4-ylamino}-benzamide	522.3	4.05 min
33	A	[3-(4-{4-[3-Methyl-4-(pyridin-2-ylmethoxy)-phenylamino]-quinazolin-6-yl]-benzyl}-3-aza-bicyclo[3.1.0]hex-6-yl)-methanol	544.3	4.41 min
34	A	(3-{4-[4-(4-Benzyloxy-phenylamino)-quinazolin-6-yl]-benzyl}-3-aza-bicyclo[3.1.0]hex-6-yl)-methanol	529.3	5.21 min
35	A	[3-(4-{4-[1-(Propane-2-sulfonyl)-1H-indol-5-ylamino]-quinazolin-6-yl]-benzyl}-3-aza-bicyclo[3.1.0]hex-6-yl)-methanol	568.3	4.73 min
36	B	8-Methyl-3-(4-{4-[1-propane-2-sulfonyl]-1H-indol-5-ylamino]-quinazolin-6-yl}-benzylamino)-8-aza-bicyclo[3.2.1]octan-6-ol	611.2	5.10 min
37	A	(3-{4-[4-(1-Benzenesulfonyl-2-methyl-1H-indol-5-ylamino)-quinazolin-6-yl]-benzyl}-3-aza-bicyclo[3.1.0]hex-6-yl)-methanol	616.2	5.47 min

TABLE (continued)

Example Number	Method of preparation	IUPAC name	LRMS (MH+)	HPLC
38	A	(3-{4-[4-(1-Benzyl-1H-indazol-5-ylamino)-quinazolin-6-yl]benzyl}-3-aza-bicyclo[3.1.0]hex-6-yl)-methanol	553.3	4.69 min
39	A	(3-{4-[4-(1-Methanesulfonyl-1H-indol-5-ylamino)-quinazolin-6-yl]benzyl}-3-aza-bicyclo[3.1.0]hex-6-yl)-methanol	540.2	4.21 min
40	A	(3-{4-[4-(1-Ethanesulfonyl-1H-indol-5-ylamino)-quinazolin-6-yl]benzyl}-3-aza-bicyclo[3.1.0]hex-6-yl)-methanol	554.2	4.47 min
41	B	(1-Benzenesulfonyl-1H-indol-5-yl)-(6-{4-[(3-oxa-bicyclo[3.1.0]hex-6-ylamino)-methyl]-phenyl}-quinazolin-4-yl)-amine	588.2	5.61 min
42	B	8-{4-[4-(1-Benzenesulfonyl-1H-indol-5-ylamino)-quinazolin-6-yl]benzyl}-8-aza-bicyclo[3.2.1]octan-3-ol	616.2	5.25 min
43	B	8-(4-{4-[1-(Propane-2-sulfonyl)-1H-indol-5-ylamino]-quinazolin-6-yl]-benzyl}-8-aza-bicyclo[3.2.1]octan-3-ol	582.2	4.84/4.96 min
44	B	8-{4-[4-(4-Phenoxyphenylamino)-quinazolin-6-yl]benzyl}-8-aza-bicyclo[3.2.1]octan-3-ol	529.3	5.35 min
45	B	8-{4-[4-(1-Benzyl-1H-indol-5-ylamino)-quinazolin-6-yl]benzyl}-8-aza-bicyclo[3.2.1]octan-3-ol	566.3 (+)	5.23 min

TABLE (continued)

Example Number	Method of preparation	IUPAC name	LRMS (MH+)	HPLC
46	A	(3-{5-[4-(4-Phenoxy-phenylamino)-quinazolin-6-yl]-pyridin-2-ylmethyl}-3-aza-bicyclo[3.1.0]hex-6-yl)-methanol	516.2	5.04 min
47	A	(3-{5-[4-(1-Benzenesulfonyl-1H-indol-5-ylamino)-quinazolin-6-yl]-pyridin-2-ylmethyl}-3-aza-bicyclo[3.1.0]hex-6-yl)-methanol	603.2	4.98 min
48	A	(3-{5-[4-(1-Benzyl-1H-indazol-5-ylamino)-quinazolin-6-yl]-pyridin-2-ylmethyl}-3-aza-bicyclo[3.1.0]hex-6-yl)-methanol	554.2	4.48 min
49	A	(3-{4-[4-(6-Phenoxy-pyridin-3-ylamino)-quinazolin-6-yl]-benzyl}-3-aza-bicyclo[3.1.0]hex-6-yl)-methanol	516.2	4.74 min
50	A	(3-{5-[4-(4-Benzyloxy-phenylamino)-quinazolin-6-yl]-pyridin-2-ylmethyl}-3-aza-bicyclo[3.1.0]hex-6-yl)-methanol	530.2	4.98 min
51	A	(3-{5-[4-(3-Methyl-4-(pyridin-2-ylmethoxy)-phenylamino)-quinazolin-6-yl]-pyridin-2-ylmethyl}-3-aza-bicyclo[3.1.0]hex-6-yl)-methanol	545.2	4.15 min
52	A	(3-{5-[4-(4-Benzyl-phenylamino)-quinazolin-6-yl]-pyridin-2-ylmethyl}-3-aza-bicyclo[3.1.0]hex-6-yl)-methanol	514.3	5.18 min
53	A	{3-[4-(4-Phenoxy-phenylamino)-quinazolin-6-ylmethyl]-3-aza-bicyclo[3.1.0]hex-6-yl}methanol	452.3	7.95 min

TABLE (continued)

Example Number	Method of preparation	IUPAC name	LRMS (MH+)	HPLC
54	B	(5-{4-[4-(1-Benzenesulfonyl-1H-indol-5-ylamino)-quinazolin-6-yl]-benzyl}-5-aza-spiro[2.5]oct-1-yl)-methanol	630.1	5.43 min
55	B	(5-{4-[4-(4-Phenoxy-phenylamino)-quinazolin-6-yl]-benzyl}-5-aza-spiro[2.5]oct-1-yl)-methanol	543.2	5.59 min
56	B	(6-{4-[4-(1-Benzenesulfonyl-1H-indol-5-ylamino)-quinazolin-6-yl]-benzyl}-6-aza-spiro[2.5]oct-1-yl)-methanol	630.2	5.36 min
57	B	(6-{4-[4-(4-Phenoxy-phenylamino)-quinazolin-6-yl]-benzyl}-6-azaspiro[2.5]oct-1-yl)-methanol	543.2	5.53 min
58	B	(5-{4-[4-(1-Benzenesulfonyl-1H-indol-5-ylamino)-quinazolin-6-yl]-benzyl}-5-aza-spiro[2.4]hept-1-yl)-methanol	616.1	5.34 min
59	B	(5-{4-[4-(4-Phenoxy-phenylamino)-quinazolin-6-yl]-benzyl}-5-aza-spiro[2.4]hept-1-yl)-methanol	529.4 (+)	5.50 min
60	B	(5-{4-[4-(4-Phenoxy-phenylamino)-quinazolin-6-yl]-benzyl}-5-aza-spiro[2.5]oct-1-yl)-methanol	543.2	5.91 min


[0067] The following compounds (and their pharmaceutically acceptable salts and solvates, and all stereoisomers including any endo and exo isomers) which are part of the present invention, may be prepared using the methods described above and/or methods familiar to those skilled in the art:

(3-{4-[4-(3-Fluoro-4-phenoxy-phenylamino)-quinazolin-6-yl]-benzyl}-3-aza-bicyclo[3.1.0]hex-6-yl)-methanol;
 (3-{4-[4-(4-Phenoxy-3-trifluoromethyl-phenylamino)-quinazolin-6-yl]-benzyl}-3-aza-bicyclo[3.1.0]hex-6-yl)-methanol;
 (3-{4-[4-(3-Chloro-4-phenoxy-phenylamino)-quinazolin-6-yl]-benzyl}-3-aza-bicyclo[3.1.0]hex-6-yl)-methanol;
 (5-{4-[4-(1-Benzenesulfonyl-1H-indol-5-ylamino)-quinazolin-6-yl]-benzyl}-5-aza-spiro[2.5]oct-1-yl)-methanol;
 8-{4-[4-(1-Benzenesulfonyl-1H-indol-5-ylamino)-quinazolin-6-yl]-benzyl}-8-aza-bicyclo[3.2.1]octan-3-ol;
 8-{4-[4-(1-Benzyl-1H-indol-5-ylamino)-quinazolin-6-yl]-benzyl}-8-aza-bicyclo[3.2.1]octan-3-ol;

8-{4-[4-(3-Chloro-4-phenoxy-phenylamino)-quinazolin-6-yl]-benzyl}-8-aza-bicyclo[3.2.1]octan-3-ol;
 8-{4-[4-(3-Methyl-4-phenoxy-phenylamino)-quinazolin-6-yl]-benzyl}-8-aza-bicyclo[3.2.1]octan-3-ol;
 8-{4-[4-[1-(Propane-2-sulfonyl)-1H-indol-5-ylamino]-quinazolin-6-yl]-benzyl}-8-aza-bicyclo[3.2.1]octan-3-ol;
 (3-{4-[4-(4-Benzyloxy-3-methyl-phenylamino)-quinazolin-6-yl]-benzyl}-3-aza-bicyclo[3.1.0]hex-6-yl)-methanol;
 [3-{4-[4-[1-(4-Methyl-benzyl)-1H-indazol-5-ylamino]-quinazolin-6-yl]-benzyl}-3-aza-bicyclo[3.1.0]hex-6-yl]-meth-
 anol;
 [3-{4-[4-[1-(4-Methoxy-benzyl)-1H-indazol-5-ylamino]-quinazolin-6-yl]-benzyl}-3-aza-bicyclo[3.1.0]hex-6-yl]-
 methanol;
 [3-{4-[4-[1-(3-Methyl-benzyl)-1H-indazol-5-ylamino]-quinazolin-6-yl]-benzyl}-3-aza-bicyclo[3.1.0]hex-6-yl]-metha-
 nol;
 (3-{4-[4-[1-(3-Methoxy-benzyl)-1H-indazol-5-ylamino]-quinazolin-6-yl]-benzyl}-3-aza-bicyclo[3.1.0]hex-6-yl)-
 methanol;
 (3-{4-[4-[1-(2-Fluoro-benzyl)-1H-indazol-5-ylamino]-quinazolin-6-yl]-benzyl}-3-aza-bicyclo[3.1.0]hex-6-yl)-meth-
 anol;
 (3-{4-[4-(3-Methoxy-4-phenoxy-phenylamino)-quinazolin-6-yl]-benzyl}-3-aza-bicyclo[3.1.0]hex-6-yl)-methanol;
 [6-{4-(6-Dimethylamino-3-aza-bicyclo[3.1.0]hex-3-ylmethyl)-phenyl]-quinazolin-4-yl}-(3-methoxy-4-phenoxy-phe-
 nyl)-amine;
 [6-{4-(6-Dimethylamino-3-aza-bicyclo[3.1.0]hex-3-ylmethyl)-phenyl]-quinazolin-4-yl}-(3-methyl-4-phenoxy-phe-
 nyl)-amine;
 (3-{3-[4-(3-Methyl-4-phenoxy-phenylamino)-quinazolin-6-yl]-benzyl}-3-aza-bicyclo[3.1.0]hex-6-yl)-methanol;
 (3-{3-[4-(3-Methoxy-4-phenoxy-phenylamino)-quinazolin-6-yl]-benzyl}-3-aza-bicyclo[3.1.0]hex-6-yl)-methanol;
 [6-{3-(6-Dimethylamino-3-aza-bicyclo[3.1.0]hex-3-ylmethyl)-phenyl]-quinazolin-4-yl}-(3-methoxy-4-phenoxy-phe-
 nyl)-amine;
 [6-{3-(6-Dimethylamino-3-aza-bicyclo[3.1.0]hex-3-ylmethyl)-phenyl]-quinazolin-4-yl}-(3-methyl-4-phenoxy-phe-
 nyl)-amine;
 [6-{3-(6-Amino-3-aza-bicyclo[3.1.0]hex-3-ylmethyl)-phenyl]-quinazolin-4-yl}-(3-methoxy-4-phenoxy-phenyl)-
 amine;
 (3-{4-[4-(3-Methyl-4-o-tolyloxy-phenylamino)-quinazolin-6-yl]-benzyl}-3-aza-bicyclo[3.1.0]hex-6-yl)-methanol;
 [3-{4-[4-(2-Methoxy-phenoxy)-3-methyl-phenylamino]-quinazolin-6-yl]-benzyl}-3-aza-bicyclo[3.1.0]hex-6-yl]-
 methanol; and,
 [3-{4-[4-(2-Fluoro-phenoxy)-3-methyl-phenylamino]-quinazolin-6-yl]-benzyl}-3-aza-bicyclo[3.1.0]hex-6-yl]-
 methanol.

Claims

1. A compound of the formula 1




1

or a pharmaceutically acceptable salt or solvate thereof, wherein:

X is N or CH;


A represents a fused 5, 6 or 7-membered ring optionally containing 1 to 4 heteroatoms which may be the same or different and which are selected from -N(R¹)-, O, and S(O)_j, wherein j is an integer from 0 to 2, the fused ring containing a total of 1, 2 or 3 double bonds inclusive of the bond in the pyridine or pyrimidine ring to which it is fused wherein the R¹ group attached to the nitrogen is absent if a double bond includes the foregoing optional nitrogen moiety -N(R¹)-, with the proviso that the fused ring does not form part of a purine and that the fused ring does not contain two adjacent O or S(O)_j atoms, and wherein the carbon atoms of the A moiety are optionally substituted by 1 to 3 R⁵ groups;

each R^1 and R^2 is independently H or C_1 - C_6 alkyl;
 R^3 is $-(CR^1R^2)_m-R^8$ wherein m is 0 or 1;
 or R^1 and R^3 are taken together with the nitrogen to which they are attached to form a group of the formula




wherein said 1-indolyl or 1-indolinyl group is optionally substituted with 1 to 3 R^5 groups;
 R^4 is $-(CR^1R^2)_t(C_6-C_{10}$ aryl) or $-(CR^1R^2)_t(4-10$ membered heterocyclic), wherein t is an integer from 0 to 5,
 wherein said R^4 groups are substituted with 1 to 3 groups independently selected from $-(CR^1R^2)_qNR^1R^9$,
 $-(CR^1R^2)_qNR^9(C_1-C_6$ alkanoyl), $-(CR^1R^2)_qO(CR^1R^2)_rR^9$, and $-(CR^1R^2)_qR^9$ wherein q and r are each independently an integer from 0 to 5, and wherein the heterocyclic, aryl and alkyl moieties of the foregoing groups are optionally substituted with 1 to 3 R^{10} groups;
 each R^5 is independently selected from halo, hydroxy, $-NR^1R^2$, C_1 - C_6 alkyl, trifluoromethyl, C_1 - C_6 alkoxy, and trifluoromethoxy;
 each R^6 and R^7 is independently selected from H, C_1 - C_6 alkyl, $-(CR^1R^2)_t(C_6-C_{10}$ aryl), and $-(CR^1R^2)_t(4-10$ membered heterocyclic), wherein t is an integer from 0 to 5, 1 or 2 ring carbon atoms of the heterocyclic group are optionally substituted with an oxo (=O) moiety, and the alkyl, aryl and heterocyclic moieties of the foregoing R^6 and R^7 groups are optionally substituted with 1 to 3 substituents independently selected from halo, cyano, nitro, $-NR^1R^2$, trifluoromethyl, trifluoromethoxy, C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, hydroxy, and C_1 - C_6 alkoxy;
 each R^8 is independently selected from $-(CR^1R^2)_t(C_6-C_{10}$ aryl) and $-(CR^1R^2)_t(4-10$ membered heterocyclic), wherein t is an integer from 0 to 5, 1 or 2 ring carbon atoms of the heterocyclic group are optionally substituted with an oxo (=O) moiety, and each of the foregoing R^8 groups is optionally substituted with 1 to 5 R^{10} groups;
 R^9 is a fused or bridged bicyclic ring or a spirocyclic ring, wherein said ring contains from 5 to 12 carbon atoms in which up to 2 carbon atoms are optionally replaced with a hetero moiety selected from O, $S(O)_j$ wherein j is an integer from 0 to 2, and $-NR^{11}$ -, provided that two O atoms, two $S(O)_j$ moieties, an O atom and a $S(O)_j$ moiety, an N atom and an S atom, or an N atom and an O atom are not attached directly to each other, and wherein said ring is saturated or partially unsaturated with up to two carbon-carbon double bonds, and the carbon atoms of said ring are optionally substituted with 1 to 4 R^{10} groups;
 or where R^2 is as $-NR^1R^9$ then R^9 optionally can be taken together with R^1 and the nitrogen to which R^1 and R^9 are attached to form a fused or bridged bicyclic ring or a spirocyclic ring, wherein said ring is saturated and contains from 5 to 12 carbon atoms in which up to 2 carbon atoms are optionally replaced with a hetero moiety selected from O, $S(O)_j$ wherein j is an integer from 0 to 2, and $-NR^{11}$ -, provided that two O atoms, two $S(O)_j$ moieties, or an O atom and a $S(O)_j$ moiety are not attached directly to each other, and wherein the carbon atoms of said rings are optionally substituted with 1 to 4 R^{10} groups;
 each R^{10} is independently selected from halo, cyano, nitro, trifluoromethoxy, trifluoromethyl, azido, hydroxy, C_1 - C_6 alkoxy, C_1 - C_{10} alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, $-C(O)R^5$, $-C(O)OR^6$, $-OC(O)R^6$, $-NR^6C(O)R^7$, $-C(O)NR^6R^7$, $-NR^6R^7$, $-NR^6OR^7$, $-SO_2NR^6R^7$, $-S(O)_j(C_1-C_6$ alkyl) wherein j is an integer from 0 to 2, $-(CR^1R^2)_t(C_6-C_{10}$ aryl), $-(CR^1R^2)_t(4-10$ membered heterocyclic), $-(CR^1R^2)_qC(O)(CR^1R^2)_t(C_6-C_{10}$ aryl), $-(CR^1R^2)_qC(O)(CR^1R^2)_t(4-10$ membered heterocyclic), $-(CR^1R^2)_qO(CR^1R^2)_t(C_6-C_{10}$ aryl), $-(CR^1R^2)_qO(CR^1R^2)_t(4-10$ membered heterocyclic), $-(CR^1R^2)_qSO_2(CR^1R^2)_t(C_6-C_{10}$ aryl), and $-(CR^1R^2)_qSO_2(CR^1R^2)_t(4-10$ membered heterocyclic), wherein q and t are each independently an integer from 0 to 5, 1 or 2 ring carbon atoms of the heterocyclic moieties of the foregoing R^{10} groups are optionally substituted with an oxo (=O) moiety, and the alkyl, alkenyl, alkynyl, aryl and heterocyclic moieties of the foregoing R^{10} groups are optionally substituted with 1 to 3 substituents independently selected from halo, cyano, nitro, trifluoromethyl, trifluoromethoxy, azido, $-OR^6$, $-C(O)R^6$, $-C(O)OR^6$, $-OC(O)R^6$, $-NR^6C(O)R^7$, $-C(O)NR^6R^7$, $-NR^6R^7$, $-NR^6OR^7$, C_1 - C_6 alkyl, C_2 - C_6 alkenyl, C_2 - C_6 alkynyl, $-(CR^1R^2)_t(C_6-C_{10}$ aryl), and $-(CR^1R^2)_t(4-10$ membered heterocyclic), wherein t is an integer from 0 to 5;
 R^{11} is H, C_1 - C_6 alkyl, $C(O)R^6$ or $-SO_2R^6$;
 and wherein any of the above-mentioned substituents comprising a CH_3 (methyl), CH_2 (methylene), or CH (methine) group which is not attached to a halogeno, SO or SO_2 group or to a N, O or S atom optionally bears on said group a substituent selected from hydroxy, halo, C_1 - C_4 alkyl, C_1 - C_4 alkoxy and $-NR^1R^2$.

2. A compound according to claim 1 wherein the A moiety of the compound of formula 1 is selected from




wherein the above A moieties bear an R^4 group as a substituent and optionally bear 1 to 3 R^5 groups as substituents.

- 35 3. A compound according to claim 1 wherein the A moiety of the compound of formula 1 is selected from




wherein the above A moieties bear an R^4 group as a substituent and optionally bear 1 to 3 R^5 groups as substituents.

4. A compound according to claim 1 wherein the A moiety of the compound of formula 1 is selected from




wherein the above A moieties bear an R^4 group as a substituent and optionally bear 1 to 3 R^5 groups as substituents.

5. A compound according to claim 1 wherein the A moiety of the compound of formula 1 is selected from



wherein the above A moieties bear an R^4 group as a substituent and optionally bear 1 to 3 R^5 groups as substituents.

6. A compound according to claim 1 wherein the A moiety of the compound of formula 1 is



wherein the above A moieties bear an R^4 group as a substituent and optionally bear 1 to 3 R^5 groups as substituents.

7. A compound according to claim 5 wherein R^4 is $-(CR^1R^2)_t(C_6-C_{10} \text{ aryl})$ or $-(CR^1R^2)_t(4-10 \text{ membered heterocyclic})$, wherein t is an integer from 0 to 5, wherein said R^4 groups are substituted with 1 to 3 groups independently selected from $-(CR^1R^2)_qNR^1R^9$, $-(CR^1R^2)_qNR^9(C_1-C_6 \text{ alkanoyl})$, $-(CR^1R^2)_qO(CR^1R^2)_rR^9$, and $-(CR^1R^2)_qR^9$ wherein q and r are each independently an integer from 0 to 3, and wherein the heterocyclic, aryl and alkyl moieties of the foregoing groups are optionally substituted with 1 to 3 R^{10} groups.
8. A compound according to claim 6 wherein R^4 is $-(CR^1R^2)_t(C_6-C_{10} \text{ aryl})$ or $-(CR^1R^2)_t(4-10 \text{ membered heterocyclic})$, wherein t is an integer from 0 to 5, wherein said R^4 groups are substituted with 1 to 3 groups independently selected from $-(CR^1R^2)_qNR^1R^9$, $-(CR^1R^2)_qNR^9(C_1-C_6 \text{ alkanoyl})$, $-(CR^1R^2)_qO(CR^1R^2)_rR^9$, and $-(CR^1R^2)_qR^9$ wherein q and r are each independently an integer from 0 to 3, and wherein the heterocyclic, aryl and alkyl moieties of the foregoing groups are optionally substituted with 1 to 3 R^{10} groups.

9. A compound according to claim 5 wherein R^3 is $-(CR^1R^2)_m-R^8$ wherein m is 0 or 1 and R^8 is selected from $-(CR^1R^2)_t$ (phenyl), $-(CR^1R^2)_t$ (pyridyl), $-(CR^1R^2)_t$ (pyrimidinyl), $-(CR^1R^2)_t$ (indolyl), $-(CR^1R^2)_t$ (indazolyl) and $-(CR^1R^2)_t$ (benzimidazolyl), wherein t is an integer from 0 to 5, and each of the foregoing R^8 groups is optionally substituted with 1 to 5 R^{10} groups.

10. A compound according to claim 6 wherein R^3 is $-(CR^1R^2)_m-R^8$ wherein m is 0 or 1 and R^8 is selected from $-(CR^1R^2)_t$ (phenyl), $-(CR^1R^2)_t$ (pyridyl), $-(CR^1R^2)_t$ (pyrimidinyl), $-(CR^1R^2)_t$ (indolyl), $-(CR^1R^2)_t$ (indazolyl) and $-(CR^1R^2)_t$ (benzimidazolyl), wherein t is an integer from 0 to 5, and each of the foregoing R^8 groups is optionally substituted with 1 to 5 R^{10} groups.

11. A compound according to claim 7 wherein R^3 is $-(CR^1R^2)_m-R^8$ wherein m is 0 or 1 and R^8 is selected from $-(CR^1R^2)_t$ (phenyl), $-(CR^1R^2)_t$ (pyridyl), $-(CR^1R^2)_t$ (pyrimidinyl), $-(CR^1R^2)_t$ (indolyl), $-(CR^1R^2)_t$ (indazolyl) and $-(CR^1R^2)_t$ (benzimidazolyl), wherein t is an integer from 0 to 5, and each of the foregoing R^8 groups is optionally substituted with 1 to 5 R^{10} groups.

12. A compound according to claim 8 wherein R^3 is $-(CR^1R^2)_m-R^8$ wherein m is 0 or 1 and R^8 is selected from $-(CR^1R^2)_t$ (phenyl), $-(CR^1R^2)_t$ (pyridyl), $-(CR^1R^2)_t$ (pyrimidinyl), $-(CR^1R^2)_t$ (indolyl), $-(CR^1R^2)_t$ (indazolyl) and $-(CR^1R^2)_t$ (benzimidazolyl), wherein t is an integer from 0 to 5, and each of the foregoing R^8 groups is optionally substituted with 1 to 5 R^{10} groups.


13. A compound according to claim 1 selected from the group consisting of:

{6-[4-(6-Amino-3-aza-bicyclo[3.1.0]hex-3-ylmethyl)-phenyl]-quinazolin-4-yl}-(4-phenoxy-phenyl)-amine;
 (3-{4-[4-(4-Benzyl-phenylamino)-quinazolin-6-yl]-benzyl}-3-aza-bicyclo[3.1.0]hex-6-yl)-methanol;
 (3-{4-[4-(4-Phenoxy-phenylamino)-quinazolin-6-yl]-benzyl}-3-aza-bicyclo[3.1.0]hex-6-yl)-methanol;
 (3-{4-[4-(1-Benzenesulfonyl-1H-indol-5-ylamino)-quinazolin-6-yl]-benzyl}-3-aza-bicyclo[3.1.0]hex-6-yl)-methanol;
 (6-{4-[(1-Aza-bicyclo[2.2.2]oct-3-ylamino)-methyl]-phenyl}-quinazolin-4-yl)-(4-phenoxy-phenyl)-amine;
 (6-{4-[(1-Aza-bicyclo[2.2.2]oct-3-ylamino)-methyl]-phenyl}-quinazolin-4-yl)-(4-benzyl-phenyl)-amine;
 6-{4-[(1-Aza-bicyclo[2.2.2]oct-3-ylamino)-methyl]-phenyl}-quinazolin-4-yl)-(1-benzenesulfonyl-1H-indol-5-yl)-amine;
 6-{4-[(3-Aza-bicyclo[3.1.0]hex-6-ylamino)-methyl]-phenyl}-quinazolin-4-yl)-(4-phenoxy-phenyl)-amine;
 3-{4-[4-(4-Benzyl-phenylamino)-quinazolin-6-yl]-benzylamino}-8-methyl-8-aza-bicyclo[3.2.1]octan-6-ol;
 (4-Benzyl-phenyl)-{6-[4-(6-methoxymethyl-3-aza-bicyclo[3.1.0]hex-3-ylmethyl)-phenyl]-quinazolin-4-yl}amine
 {6-[4-(6-Methoxymethyl-3-aza-bicyclo[3.1.0]hex-3-ylmethyl)-phenyl]-quinazolin-4-yl}-(4-phenoxy-phenyl)-amine;
 (3-{4-[4-(4-[1,2,3]Thiadiazol-5-yl-phenylamino)-quinazolin-6-yl]-benzyl}-3-aza-bicyclo[3.1.0]hex-6-yl)-methanol;
 (3-{4-[4-(4-Cyclohexyl-phenylamino)-quinazolin-6-yl]-benzyl}-3-aza-bicyclo[3.1.0]hex-6-yl)-methanol;
 (3-{4-[4-(4-p-Tolyloxy-phenylamino)-quinazolin-6-yl]-benzyl}-3-aza-bicyclo[3.1.0]hex-6-yl)-methanol;
 (3-{4-[4-(Biphenyl-4-ylamino)-quinazolin-6-yl]-benzyl}-3-aza-bicyclo[3.1.0]hex-6-yl)-methanol;
 (3-{4-[4-(4-Ethyl-phenylamino)-quinazolin-6-yl]-benzyl}-3-aza-bicyclo[3.1.0]hex-6-yl)-methanol;
 4-{6-[4-(6-Hydroxymethyl-3-aza-bicyclo[3.1.0]hex-3-ylmethyl)-phenyl]-quinazolin-4-ylamino}-N-phenyl-benzamide;
 [3-{4-[4-(1-(Propane-2-sulfonyl)-1H-indol-5-ylamino)-quinazolin-6-yl]-benzyl}-3-aza-bicyclo[3.1.0]hex-6-yl]-methanol;
 (3-{4-[4-(1-Benzyl-1H-indazol-5-ylamino)-quinazolin-6-yl]-benzyl}-3-aza-bicyclo[3.1.0]hex-6-yl)-methanol;
 {1-Benzenesulfonyl-1H-indol-5-yl}-(6-{4-[(3-oxa-bicyclo[3.1.0]hex-6-ylamino)-methyl]-phenyl}-quinazolin-4-yl)-amine;
 8-{4-[4-(1-Benzenesulfonyl-1H-indol-5-ylamino)-quinazolin-6-yl]-benzyl}-8-aza-bicyclo[3.2.1]octan-3-ol;
 8-{4-[4-(1-(Propane-2-sulfonyl)-1H-indol-5-ylamino)-quinazolin-6-yl]-benzyl}-8-aza-bicyclo[3.2.1]octan-3-ol;
 8-{4-[4-(4-Phenoxy-phenylamino)-quinazolin-6-yl]-benzyl}-8-aza-bicyclo[3.2.1]octan-3-ol;
 8-{4-[4-(1-Benzyl-1H-indol-5-ylamino)-quinazolin-6-yl]-benzyl}-8-aza-bicyclo[3.2.1]octan-3-ol;
 (3-{4-[4-(6-Phenoxy-pyridin-3-ylamino)-quinazolin-6-yl]-benzyl}-3-aza-bicyclo[3.1.0]hex-6-yl)-methanol;
 (3-{5-[4-(4-Benzyl-phenylamino)-quinazolin-6-yl]-pyridin-2-ylmethyl}-3-aza-bicyclo[3.1.0]hex-6-yl)-methanol;
 {3-[4-(4-Phenoxy-phenylamino)-quinazolin-6-ylmethyl]-3-aza-bicyclo[3.1.0]hex-6-yl}methanol;
 (5-{4-[4-(1-Benzenesulfonyl-1H-indol-5-ylamino)-quinazolin-6-yl]-benzyl}-5-aza-spiro[2.5]oct-1-yl)-methanol;


(5-{4-[4-(4-Phenoxy-phenylamino)-quinazolin-6-yl]-benzyl}-5-aza-spiro[2.5]oct-1-yl)-methanol;
 (6-{4-[4-(1-Benzenesulfonyl-1H-indol-5-ylamino)-quinazolin-6-yl]-benzyl}-6-aza-spiro[2.5]oct-1-yl)-methanol;
 (6-{4-[4-(4-Phenoxy-phenylamino)-quinazolin-6-yl]-benzyl}-6-azaspiro[2.5]oct-1-yl)-methanol;
 (5-{4-[4-(1-Benzenesulfonyl-1H-indol-5-ylamino)-quinazolin-6-yl]-benzyl}-5-aza-spiro[2.4]hept-1-yl)-methanol;
 (5-{4-[4-(4-Phenoxy-phenylamino)-quinazolin-6-yl]-benzyl}-5-aza-spiro[2.4]hept-1-yl)-methanol;
 (5-{4-[4-(4-Phenoxy-phenylamino)-quinazolin-6-yl]-benzyl}-5-aza-spiro[2.5]oct-1-yl)-methanol;
 and the pharmaceutically acceptable salts and solvates of the foregoing compounds.

14. A pharmaceutical composition including a compound of the formula I, or a pharmaceutically acceptable salt or solvate thereof, as claimed in any one of the preceding claims, together with a pharmaceutically acceptable diluent or carrier.
15. A compound of the formula I, or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutically acceptable composition thereof, as claimed in any one of claims 1 to 13 or 14 respectively, for use as a medicament.
16. The use of a compound of the formula I, or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutically acceptable composition thereof, as claimed in any one of claims 1 to 13 or 14 respectively, for the manufacture of a medicament for the treatment of abnormal cell growth in a mammal.
17. A use according to claim 16 wherein said abnormal cell growth is cancer.
18. A use according to claim 17 wherein said cancer is selected from lung cancer, bone cancer, pancreatic cancer, skin cancer, cancer of the head or neck, cutaneous or intraocular melanoma, uterine cancer, ovarian cancer, rectal cancer, cancer of the anal region, stomach cancer, colon cancer, breast cancer, uterine cancer, carcinoma of the fallopian tubes, carcinoma of the endometrium, carcinoma of the cervix, carcinoma of the vagina, carcinoma of the vulva, Hodgkin's Disease, cancer of the esophagus, cancer of the small intestine, cancer of the endocrine system, cancer of the thyroid gland, cancer of the parathyroid gland, cancer of the adrenal gland, sarcoma of soft tissue, cancer of the urethra, cancer of the penis, prostate cancer, chronic or acute leukemia, lymphocytic lymphomas, cancer of the bladder, cancer of the kidney or ureter, renal cell carcinoma, carcinoma of the renal pelvis, neoplasms of the central nervous system (CNS), primary CNS lymphoma, spinal axis tumors, brain stem glioma, pituitary adenoma, or a combination of one or more of the foregoing cancers.
19. A use according to claim 16 wherein said abnormal cell growth is a benign proliferative disease.
20. A use according to claim 19 wherein said abnormal cell growth is selected from psoriasis, benign prostatic hypertrophy and restinosis.
21. A pharmaceutical composition including a compound of the formula I, or a pharmaceutically acceptable salt or solvate thereof, as claimed in any one of claims 1 to 13, in combination with an anti-tumor agent selected from mitotic inhibitors, alkylating agents, anti-metabolites, intercalating antibiotics, growth factor inhibitors, cell cycle inhibitors, enzymes, topoisomerase inhibitors, biological response modifiers, antibodies, cytotoxics, anti-hormones, and anti-androgens and a pharmaceutically acceptable diluent or carrier.
22. A product including a compound of the formula I, or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutically acceptable composition thereof, as claimed in any one of claims 1 to 13 or 14 respectively, and an anti-tumor agent selected from mitotic inhibitors, alkylating agents, anti-metabolites, intercalating antibiotics, growth factor inhibitors, cell cycle inhibitors, enzymes, topoisomerase inhibitors, biological response modifiers, antibodies, cytotoxics, anti-hormones, and anti-androgens as a combined preparation for simultaneous, separate or sequential use in treating abnormal cell growth.
23. The use of a compound of the formula I, or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutically acceptable composition thereof, as claimed in any one of claims 1 to 13 or 14 respectively, in combination with an anti-tumor agent selected from mitotic inhibitors, alkylating agents, anti-metabolites, intercalating antibiotics, growth factor inhibitors, cell cycle inhibitors, enzymes, topoisomerase inhibitors, biological response modifiers, antibodies, cytotoxics, anti-hormones, and anti-androgens for the manufacture of a medicament for the treatment of abnormal cell growth in a mammal.


24. The use of a compound of the formula I, or a pharmaceutically acceptable salt or solvate thereof, or a pharmaceutically acceptable composition thereof, as claimed in any one of claims 1 to 13 or 14 respectively, for the manufacture of a medicament for the treatment of abnormal cell growth in a mammal for administration separately, sequentially or simultaneously with an anti-tumor agent selected from mitotic inhibitors, alkylating agents, anti-metabolites, intercalating antibiotics, growth factor inhibitors, cell cycle inhibitors, enzymes, topoisomerase inhibitors, biological response modifiers, antibodies, cytotoxics, anti-hormones, and anti-androgens.
25. A method of preparing a compound of claim 1 which comprises either (a) reacting a compound of the formula 5 with a compound of the formula 6




wherein Z is a leaving group and A, X, R¹, R³, and R⁴ are as defined in claim 1, or (b) reacting a compound of the formula 2 with a compound of the formula 6



wherein X, A, R¹, and R³ are as defined in claim 1 and Z¹ is an activating group, to provide an intermediate of the formula 7



wherein Z¹, X, A, R¹, and R³ are as defined in claim 1, and treating the compound of formula 7 with a coupling partner of the formula X¹-(CR¹R²)_t(C₆-C₁₀ aryl) or X¹-(CR¹R²)_t(4-10 membered heterocyclic), wherein t, R¹ and R² are as defined in claim 1 as provided in the definition of R⁴, the aryl and heterocyclic groups of the foregoing groups are substituted with a group that includes an aldehyde or acid moiety, and X¹ is -B(OH)₂ or -Sn(C₁-C₅ alkyl)₃, to provide a compound of formula 8



15 wherein X, A, R¹, and R³ are as defined above, and Z² is -(CR¹R²)_t(C₆-C₁₀ aryl) or -(CR¹R²)_t(4-10 membered heterocyclic), wherein t, R¹ and R² are as defined in claim 1, and the aryl and heterocyclic groups of the foregoing Z² groups are substituted with a group that includes an aldehyde or acid moiety, and modifying said aldehyde or acid moiety to introduce a group selected from -(CR¹R²)_qNR¹R⁹, -(CR¹R²)_qNR⁹(C₁-C₆ alkanoyl), -(CR¹R²)_qOR⁹, and -(CR¹R²)_qR⁹, wherein R¹, R², R⁹ and q are as defined in the definition of R⁴ in claim 1.

20

25

30

35

40

45

50

55



European Patent
Office

PARTIAL EUROPEAN SEARCH REPORT

Application Number

which under Rule 45 of the European Patent Convention EP 99 31 0574
shall be considered, for the purposes of subsequent
proceedings, as the European search report

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Y	SPADA A P ET AL: "SMALL MOLECULE INHIBITORS OF TYROSINE KINASE ACTIVITY" EXPERT OPINION ON THERAPEUTIC PATENTS, GB, ASHLEY PUBLICATIONS, vol. 5, no. 8, 1 January 1995 (1995-01-01), pages 805-817, XP000567587 ISSN: 1354-3776 * page 806, right-hand column - page 808, left-hand column *	6, 8, 10, 12, 13	C07D239/94 C07D453/02 C07D451/02 A61K31/505 A61P35/00
Y	WO 97 30034 A (ZENECA LTD) 21 August 1997 (1997-08-21) * claims 1, 7, 10; examples 8, 9, 37 *	6, 8, 10, 12, 13	
X	WO 98 02434 A (COCKERILL GEORGE STUART; GUNTRIP STEPHEN BARRY (GB); GLAXO GROUP L) 22 January 1998 (1998-01-22) * page 11, line 19 - line 35; claim 1; examples 1, 5, 10 *	6, 8, 10, 12, 13	
Y	WO 95 19774 A (WARNER LAMBERT CO) 27 July 1995 (1995-07-27) * claim 1; example 1; table 1 *	6, 8, 10, 12, 13	
-/-			TECHNICAL FIELDS SEARCHED (Int.Cl.7) C07D A61K A61P
INCOMPLETE SEARCH			
<p>The Search Division considers that the present application, or one or more of its claims, does/do not comply with the EPC to such an extent that a meaningful search into the state of the art cannot be carried out, or can only be carried out partially, for these claims.</p> <p>Claims searched completely :</p> <p>Claims searched incompletely :</p> <p>Claims not searched :</p> <p>Reason for the limitation of the search:</p> <p style="text-align: center;">see sheet C</p>			
Place of search MUNICH		Date of completion of the search 10 May 2000	Examiner Härtinger, S
<p>CATEGORY OF CITED DOCUMENTS</p> <p>X : particularly relevant if taken alone Y : particularly relevant if combined with another document of the same category A : technological background O : non-written disclosure P : intermediate document</p> <p>T : theory or principle underlying the invention E : earlier patent document, but published on, or after the filing date D : document cited in the application L : document cited for other reasons & : member of the same patent family, corresponding document</p>			

EPO FORM 1603 03.02 (P4/C07)



European Patent
Office

INCOMPLETE SEARCH
SHEET C

Application Number
EP 99 31 0574

Claim(s) searched completely:
6,8,10,12,13

Claim(s) searched incompletely:
1-5,7,9,11,14-25

Reason for the limitation of the search:

Present claims 1-5,7,9,11 and 14-25 relate to an extremely large number of possible products, uses and methods. Support within the meaning of Article 84 EPC and/or disclosure within the meaning of Article 83 EPC is to be found, however, for only a very small proportion of the compounds, uses and methods claimed. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Consequently, the search has been carried out for those parts of the claims which appear to be supported and disclosed, namely those parts relating to quinazoline derivatives as defined in the claims 6, 8, 10, 12 and 13, i.e. the compounds of formula I, wherein the ring A represents a benzene ring.

PARTIAL EUROPEAN SEARCH REPORT

Application Number
EP 99 31 0574

DOCUMENTS CONSIDERED TO BE RELEVANT			CLASSIFICATION OF THE APPLICATION (Int.Cl.7)
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	
A	EP 0 882 717 A (KYOWA HAKKO KOGYO KK) 9 December 1998 (1998-12-09) * page 5, line 55 - line 58; claim 1; examples 14,139,170 * * page 7, line 3 - line 10 * -----	6,8,10. 12,13	TECHNICAL FIELDS SEARCHED (Int.Cl.7)

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 99 31 0574

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

10-05-2000

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9730034 A	21-08-1997	AU 707339 B	08-07-1999
		AU 1612697 A	02-09-1997
		CA 2242102 A	21-08-1997
		CN 1211240 A	17-03-1999
		EP 0880507 A	02-12-1998
		NO 983707 A	13-10-1998
		US 5866572 A	02-02-1999
WO 9802434 A	22-01-1998	AU 3766897 A	09-02-1998
		EP 0912559 A	06-05-1999
		ZA 9706147 A	11-01-1999
WO 9519774 A	27-07-1995	US 5654307 A	05-08-1997
		AU 686334 B	05-02-1998
		AU 1731495 A	08-08-1995
		AU 686339 B	05-02-1998
		AU 1833495 A	08-08-1995
		BG 100614 A	31-03-1997
		BG 100615 A	28-02-1997
		CA 2177372 A	27-07-1995
		CA 2177392 A	27-07-1995
		CN 1139383 A	01-01-1997
		CN 1139430 A	01-01-1997
		CZ 9601970 A	17-09-1997
		CZ 9601971 A	16-07-1997
		EP 0742717 A	20-11-1996
		EP 0741711 A	13-11-1996
		FI 962855 A	13-09-1996
		FI 962856 A	25-09-1996
		HR 950033 A	31-10-1997
		HR 950034 A	31-10-1997
		HU 74590 A	28-01-1997
		HU 74589 A	28-01-1997
		JP 9508126 T	19-08-1997
		JP 9508127 T	19-08-1997
		MD 960211 A	30-04-1998
		MD 960217 A	30-04-1998
		NO 963093 A	24-07-1996
		NO 963094 A	24-07-1996
		NZ 281404 A	28-05-1999
		PL 315632 A	25-11-1996
		PL 315633 A	25-11-1996
		SK 89496 A	08-10-1997
		SK 89596 A	06-08-1997
		WO 9519970 A	27-07-1995
		US 5679683 A	21-10-1997

EPO FORM P-489

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82

**ANNEX TO THE EUROPEAN SEARCH REPORT
ON EUROPEAN PATENT APPLICATION NO.**

EP 99 31 0574

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on
The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

10-05-2000

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO 9519774 A		ZA 9500441 A	10-10-1995
		ZA 9500440 A	10-10-1995
EP 0882717 A	09-12-1998	AU 4470897 A	24-04-1998
		NZ 330571 A	28-10-1999
		CA 2239227 A	09-04-1998
		CN 1208404 A	17-02-1999
		WO 9814431 A	09-04-1998

EPO FORM P0458

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82